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SUMMARY
The pharmacokinetics of D-penicillamine were 
investigated in normal rats and an experimental animal 
model of arthritis, namely the adjuvant arthritic rat. 
Total serum D-penicillamine (i.e. free, protein-bound 
and all disulphide metabolites) levels were assayed by 
means of an HPLC system coupled to a gold-mercury 
electrochemical detector. D-penicillamine was well 
absorbed from the gut, oral bioavailability being 68%. 
The elimination of the drug from serum was shown to be 
tri-phasic. An initial phase with a very short 
half-life of approximately 3 minutes, was followed by a 
an elimination phase with a half-life of 27 minutes. 
The final, slower phase had a half-life of 51 hours.
The major metabolite identified in the serum of the rat 
was the symmetrical penicillamine disulphide. Free 
D-penicillamine was initialy present at approximately 
4% of the total but was undetectable after 3 hours. 
Penicillamine cysteine was not detected.
The kinetics of penicillamine cysteine (the major 
metabolite in human blood) and penicillamine disulphide 
(the major metabolite in rat blood) were examined after 
oral and intravenous administration of each diulphide. 
Oral bioavailabilty of penicillamine cysteine was 48.1% 
whilst penicillamine disulphide was poorly absorbed,
oral bioavailability being less than 3%. Whilst the 
kinetics of penicillamine cysteine closely resembled 
D-penicillamine kinetics, penicillamine disulphide was 
shown to be eliminated much faster than the parent 
drug. Almost 70% of the intravenous dose appeared in 
the urine within 4 hours of dosing as compared to 45% 
after an intravenous dose of either D-penicillamine or 
penicillamine cysteine.
The effects of D-penicillamine and penicillamine 
cysteine on the development of rat adjuvant arthritis 
were assessed. Neither compound was found to alter the 
course of the disease, nor was the metabolism of either 
compound affected by the disease. The relevance of 
these results with regard to the studies performed in 
man and the suitability of rat adjuvant arthritis as a 
suitable model for the screening of potential 
anti-rheumatic drugs are discussed.
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2The introduction to this thesis is divided into three 
sections. It begins with a summary of the background of 
D-penicillamine followed by a review of the work 
performed, to date, on the metabolism of the drug in 
man and animals. Finally, there is an overview of the 
experimental models of rheumatoid arthritis.
1.1. D-PENICILLAMINE
1.1.1 Structure and Chemistry of D-Penicillamine
D-Penicillamine was first isolated and identified in 
1943 by Abraham and his coworkers during their attempts 
to elucidate the structure of penicillin (Abraham et 
al, 1943). This penicillin-hydrolysis product is a
trifunctional amino acid, structurally similar to the 
naturally occurring amino acid, cysteine. It differs 
from cysteine in that two methyl groups replace the 
hydrogen atoms at the f3 - carbon, hence the generic 
name f3*D*dimethylcysteine (Fig. 1.1). The asymetrical
CXcarbon atom enables it to exist as either the D- or 
L- stereoisomer and, if synthesized from a racemic 
precursor, is present in both forms. The two 
enantiomers exhibit distinctly different metabolic and 
toxicological profiles (Kuchinskas et al, 1957) and it 

















Fig. 1.1. Comparison of the Structures of 
D-Penicillamine and L-Cysteine
4therapeutcally. D-Penicillamine is laevorotatory in 
solution, hence the proper designation
D(-)Penicillamine. In aqueous solutions, penicillamine 
is slowly oxidised to penicillamine disulphide, this 
reaction being facilitated by the presence of air, 
traces of heavy metals light, raised temperatures and 
alkalinity (Doornbos and Feitsma, 1967).
As shown in Figure 1.1, D-Penicillamine posesses three 
funtional groups; a carbonyl, a sulphydryl and an amino 
group. These three different functional moieties 
enable D-Penicillamine to take part in diverse 
reactions characteristic of each group. These 
biochemical properties are summarised in Table 1. The 
capacity of D-Penicillamine to participate in such 
diverse reactions has lead to its use in the treatment 
of a variety of seemingly unrelated diseases
1.1.2. Therapeutic Applications of D-Penicillamine.
The first reported therapeutic use of D-Penicilamine 
was not until thirteen years after its discovery. 
Wilson's disease (hepatolenticular degeneration) is a 
genetic disorder resulting in the excessive deposition 
of copper in tissues. In 1956 Walsche (Walsche 1956), 
realizing the metal chelating ability of 
D-penicillamine, speculated and subsequently proved the 
usefulness of the compound in the treatment of this
I5
(a) Complex formation.
(i) P-SH + heavy metals <— —> (PSH)-metal
(Cu, Zn)
(ii) P-SH + pyridoxal <— thiazolidine
derivative
(b) Disulphide Formation.
(i) P-SH + thiol-SH <— —> P-S-S-thiol
(P-SH, cysteine)
(ii) P-SH + protein-SH <— P-S-S-protein
(c) Thiol-Disulphide Exchange.
(i) P-SH + disulphide <——> P-S-S-thiol +
(thiol-S-S-thiol) thiol-SH
(ii) P-SH + protein S-S-thiol <——> P-S-S-protein
+ thiol SH
(d) Methylation.





Table 1. Biochemical Reactions of 
D-Penicillamine.
disease. As a result of its ability to chelate copper, 
D-Penicillamine complexes with albumin bound copper 
releasing it from proteins thereby rendering it
available for filtration at the glomerulus. Plasma 
copper levels are replaced from tissue stores and an 
equilibrium is reached between the protein-metal bonds 
in plasma and tissues (Kekki et al, 1966).
As with Wilson's Disease, the chelating ability of 
penicillamine has lead to its use in the treatment of 
certain heavy metal poisonings. The administration of 
D-penicillamine to hyperactive children with raised 
blood lead levels has proved to be therapeutically 
effective by promoting urinary lead excretion (Darrow 
and Schroeder, 1974). In their critical review of 
mercurial toxicity, MacGregor and Clarkson (1974) 
report that D-penicillamine is an effective oral 
antidote to mercuric chloride and that the acetyl 
derivative is also effective against mercury vapour
intoxication. Although D-penicillamine can complex with 
iron, it does not deplete iron stores or reduce serum 
iron (Lyle, 1979). Serum zinc levels are thought to be
unaffected but zinc depletion has been found to occur
at a cellular level in patients with generalized 
scleroderma treated with penicillamine (Jepson and 































Table 2. Therapeutic Applications of
D-Penicillamine (from Lyle, 1979)
8In addition to his predictions about the value of 
D-penicillamine in the treatment of Wilson's Disease, 
Walsche (1956) also hypothesized that the capacity of 
penicillamine to take part in thiol-disulphide exchange 
reactions could be beneficial in the treatment of 
cystinuria, an hereditary disorder of amino acid 
transport resulting in the deposition of cystine 
crystals in the kidney. The mechanism of action of 
D-penicillamine in this disease is to react with 
cystine to form the more soluble compound, 
penicillamine-cysteine disulphide. The formation of 
this readily excretable disulphide reduces "cystine 
stone" formation in renal tubules. However , it was 
left to Crawhall and his coworkers to prove the 
rationale behind this theory correct (Crawhall et al,
1963).
The potential of penicillamine to cleave disulphide 
bonds was further demonstrated in vitro with 
macroglobulins (Ritzman et al, 1960). This finding led 
Jaffe to theorize that if penicillamine could cleave 
the macroglobulin rheumatoid factor (RF), the disease 
process might be interrupted. However, although a short 
course of injections of penicillamine into the knee 
joint lowered the titre of RF in the synovial fluid, it 
did not relieve the symptoms (Jaffe, 1962). Systemmic 
administration of the drug over several months
9eventually brought about a reduction of serum RF, 
clinical improvement becoming evident first. 
Furthermore cessation of therapy was not followed by a 
return of pretreatment RF levels until many weeks 
later. It is now well established that any clinical 
improvement in rheumatoid patients in response to
penicillamine is seen only after a iatent period of 
several weeks. Also, whilst in some patients the 
response may be drammatic, others may show little or no 
improvement. In addition, there is an alarming 
incidence of adverse reactions amongst rheumatoid 
arthritis (RA) patients. The major side-effects of the 
drug will be dealt with later.
1.1.3 Possible Mechanisms of Action of D-Penicillamine 
in Rheumatoid Arthritis.
As previously discussed, D-penicillamine has an
established role in the treatment of three unrelated
disorders; Wilson's Disease, cystinuria and rheumatoid 
arthritis. In the first two, its mode of action is 
fairly well understood. However, in RA it remains 
speculative mainly because the pathogenesis and 
pathological dynamics of the disease are unclear.
Considering the number of biochemical reactions in
which penicillamine might interfere there have been
10
many proposed mechanisms described for the therapeutic 
action of the drug. In active RA, serum copper and 
caeruloplasmin (the major copper carrying protein in 
plasma) are maintained at higher levels. These levels 
tend to fall towards normal when the disease activity 
is suppressed by penicillamine (Scudder et al, 1978). 
However, the ability of penicillamine to promote copper 
excretion is unlikely to be beneficial per se. Jayson 
et al ( 1976) have shown that serum copper and 
caeruloplasmin levels are simmilarly raised in 
ankylosing spondylitis, a disease in which penicilamine 
treatment is usually ineffective. Nevertheless 
displacement of copper from protein bound sites and 
subsequent complex formation and redistribution may be 
of importance.
Another proposed mode of action of D-penicillamine is 
the scavenging of oxygen derived radicals (ODR's) 
produced by phagocytes penetrating inflammatory sites. 
The hydroxyl (0H‘) radical, generally considered to be 
the most reactive of these species, is formed from 
superoxide anion 02* and H2^2 Presence °f
transition metal ions, generally iron (Gutteridge et 
al, 1982). These radicals are deleterious for cell 
membranes and for the polysaccharides present in the 
synovial fluid (McCord, 1974). The chelate formed with 
penicillamine has been shown to have superoxide 
dismutating activity, thus the removal of the anion
11
necessary for OH' formation (Greenwald and Moy, 1980) 
may account for some of the beneficial effects seen 
with D-penicillamine. Indeed, Sorenson (1976) proved 
that copper complexes of many anti-inflammatory drugs, 
including D-penicillamine, are more active than their 
parent compounds in several experimental inflammatory 
models. In addition, chelation of the iron that 
catalyses OH' formation may also protect the joint from 
the destructive effects of these radicals. However, it 
should be remembered that chelation of iron by 
D-penicillamine is relatively poor in comparison with 
that seen with lead or copper ions (Doornbos and Faber,
1964).
Copper is also an essential requirement for the enzyme 
lysyl oxidase which is responsible for collagen 
cross-linking (Nimni, 1977). Since the concentrations 
of penicillamine required in vitro to inhibit this 
enzyme (and other enzymes with metals as cofactor) 
greatly exceed those reached in vivo (Siegel, 1977), 
interference with collagen cross-linking by this method 
seems unlikely. However, since penicillamine contains 
both a thiol and an amino group it can form lysyl and 
hydroxylysyl derived aldehydes (Nimni, 1977; Siegel,
1977). It has been proposed that the significance of 
this reaction is a stabilising effect on collagen 
making it less susceptible to degradation (Crawhall et 
al, 1979). Gerber (1978) proposed that D-penicillamine
12
may mimic the action of collagenase inhibitors due to 
disulphide exchange reactions thereby regulating 
collagenase activity in the rheumatoid joint. This same 
author has shown that, in vitro, the drug inhibits the 
sulphydryl dependent heat denaturation of IgG (Gerber,
1978) and so might prevent the formation of 
autoantigenic IgG aggregates in vivo. However, there is 
some dispute as to whether the levels of free 
D-penicillamine reached in plasma are sufficient to 
cause such an effect (Giacomello, 1981).
In addition to these biochemical effects, 
D-penicillamine has a profound effect on the immune 
response in the disease, suggesting an immunoregulatory 
mechanism of the drug. In vitro mitogen-induced 
lymphocyte proliferation can be enhanced at low doses 
of D-penicillaimne and inhibited at higher doses (Room 
et al, 1979). D-penicillamine has also been shown to 
synergise with copper ions in vitro to suppress 
lymphocyte function by inhibiting T-cell function 
(Lipsky and Ziff, 1980). This has been attributed to 
the generation of hydrogen peroxide by the 
penicillamine-copper complexes which suppress T-cell 
activity (Lipsky, 1984). However, no convincing T-cell 
activity in vivo by D-penicillamine has yet been shown. 
Evidence has been produced indicating a possible 
immuno-regulatory role for D-penicillamine in RA by 
affecting thiol-dependent reactions of monocytes
13
(McKeown et al, 19 84).
This interference in the immune system may, in part, be 
responsible for a number of the adverse reactions 
observed with D-penicillamine. Coleman and coworkers 
(1986) have shown the existence of drug-specific 
antibodies against captopril, a thiol containing drug 
structurally related to D-penicillamine and whose 
side-effects are similar in many respects to those of 
D-penicillamine. As both drugs are extensively protein 
bound via disulphide linkages they may be acting as 
haptens to induce drug-specific antibody responses, 
thus leading to a state of hypersensitivity.
1.1.4. Adverse Effects of D-Penicillamine.
Commencement of penicillamine therapy in rheumatoid 
arthritis patients follows generally the same 
indications for the employment of chrysotherapy. 
Patients who are sufficiently active and who have 
failed to respond to treatment with non-steroidal 
anti-inflammatory drugs are candidates for treatment 
with penicillamine. In 1973 a multicentre trial not 
only demonstrated the efficacy of penicillamine as an 
anti-rheumatic agent, but also highlighted its capacity 
to induce the adverse reactions listed in Table 3. 
(Andrews et al, 1973). This is in sharp contrast to its
14
Common Side Effects
Gastrointestinal Upset Early Rash
Diarrhoea Thrombocytopenia
Buccal Ulceration Leukopenia
Alterations in Taste Proteinuria
Uncommon Side Effects
Aplastic Anaemia Good Pasture's Syndrome
Systemmic Lupus Febrile Reactions
Erythematosus Myasthenic Syndrome
Nephrotic Syndrome Pemphigus
Table 3. Adverse Reactions in D-Penicillamine 
Therapy.
use in Wilson's Disease and cystinuria where much 
higher doses are well tolerated. As a result of the 
alarming incidence of side effects in rheumatoid 
patients a dosage regimen of "go low, go slow" is 
generally employed. Patients are started on 125-250 mg 
daily and the dosage raised by degrees over several 
weeks until a maintenace dose (500 - 1000 mg daily) is 
reached at which the patient shows clear signs of 
improvement. The side effects, whilst being 
unpleasant, are mostly not serious and are reversible 
upon cessation of treatment. Amongst the commonest of 
problems encountered with D-penicillamine therapy are 
nausea, skin rashes and loss of taste all of which 
occur in approximately 25% of patients. "Early" and 
"late" rashes disappear on cessation of therapy and 
generally do not recur on recommencement of treatment. 
Taste usually returns whether therapy is discontinued 
or not. A more important complication is proteinuria 
and may lead to withdrawal of the drug. Its incidence 
and severity are variable and dose related - Crawhall 
(1981) reports proteinuria occurred in 30% of patients 
receiving in excess of 750 mg daily for more than six 
months. In some of these cases nephrotic syndrome can 
occur. It is essential to monitor renal function during 
penicillamine treatment. Haematological abnormalites 
can also occur, of which thrombocytopenia is the most 
common. When this occurs, treatment is usually 
discontinued to facilitate recovery but can generally
16
be cautiously restarted. More serious effects (but 
fortunately less common) include neutropenia, blood 
dyscrasias and drug-induced systemmic lupus 
erythematosus (SLE).
The precise reasons for such inter-individual 
variations in both efficacy and toxicity to 
D-penicillamine are as yet unknown. However, it may be 
in part be related to plasma levels of the drug and/or 
its metabolites. In order to test the validity of this 
hypothesis, a precise and accurate method of analysis 
for D-penicillamine and its metabolites is a 
pre-requisite.
1.1.5 Assays for D-Penici11amine in Biological Fluids.
Pharmacokinetic studies have so far been hampered by 
the lack of reliable, sensitive and selective methods 
for the determination of D-penicillamine and its 
metabolites. The inherent reactivity of penicillamine 
has proved to be a considerable problem. Only in recent 
years have procedures been adopted which have 
eliminated problems in penicillamine analysis. These 
have been mainly the use of EDTA to chelate any metal 
ions present, thereby preventing penicillamine 
chelation, and manipulation of the pH to keep the drug 
in the desired form (Bergstrom et al, 1980). The
17
analytical methods employed to date can be separated 
into two groups: non-chromatographic and
chromatographic. The first category encompasses 
spectrophotometry, which is limited by its lack of 
sensitivity and selectivity (Pal, 1959), and 
radioimmunoassay (RIA). The use of RIA is restricted by 
the relative unavailability of radiolabelled 
D-penicillamine and its metabolites required to produce 
specific antisera (Assem and Vickers, 1974).
Determination of penicillamine levels by 
chromatographic techniques such as amino acid analysis 
with ninhydrin detection (Friedman et al, 1977), and 
gas-liquid chromatography (Jellum et al, 1969) may 
provide quantitative information about the metabolism 
of the parent drug and its metabolites. However, 
resolution of these compounds from other amino acids 
requires time consuming analysis programmes for 
physiological fluids. In general this renders these 
methods unsuitable for large sample investigations such 
as those required for pharmacokinetic studies. Also, 
they assume that the metabolites are both known and are 
available as standards.
In recent years the convenience and versatility of high 
performance liquid chromatography (HPLC) has lead to 
its acceptance as one of the most useful techniques 
available for the analysis of drugs in biological
18
fluids. Due to the lack of a chromophore in the
penicillamine molecule, low concentrations cannot be 
detected in the ultraviolet region. However, in recent 
years several HPLC methods using electrochemical
detection have been described (Saetre and Rabenstein, 
1978; Bergstrom et al, 1981 and Kreuzig and Frank,
1981). Although these methods are reliable and rapid,
none of them allows the direct determination of 
individual metabolites. All the methods rely on the 
reduction of all penicillamine moieties (ie. all 
metabolites and protein bound penicillamine) back to 
the free thiol. To date, the direct measurement of 
individual penicillamine metabolites by a quick, 
reliable method remains to be perfected. Such an assay 
would permit full metabolic profiles for rheumatoid 
arthritic patients to be determined and correlation 
studies may shed light on the on the mechanisms by 
which penicillamine exerts its clinical benefit and 
produces side effects. In addition there is no
satisfactory analytical procedure to measure the only 
truly "metabolised" form of penicillamine - the 
S-methyl derivative. This metabolite has been detected 
in plasma (Muijsers et al, 1979) and urine (Perret et 
al, 1975). In this project "total" d-penicillamine is 
measured by . a modification of the method described by 
Abounassif and Jefferies (1983) employing a
gold-mercury electrochemical detector specific for
thiols. This method requires that samples must be
19
initially treated with the reducing agent 
Di-thiothreitol (Cleland's Reagent; Cleland, 1964). The 
oxidised disulphide forms of D-penicillamine are thus 
reduced to the SH-form, suitable for measurement by the 
HPLC system.
20
1.2. THE METABOLISM OF D-PENICILLAMINE •
As discussed previously, the recent development of more 
sensitive, reliable assays for D-penicillamine in 
biological fluids and tissue has allowed greater in 
depth studies on the metabolism of D-penicillamine. 
Pharmacokinetic studies of the drug and its metabolites 
may be important when trying to correlate the incidence 
of side effects or variation of efficacy to circulating 
levels of the drug or metabolites.
The hitherto identified metabolites of D-penicillamine 
are shown in Figure 1.2. The metabolism of the drug is 
predominantly governed by its ability to interfere with 
thiol-disulphide exchange reactions. Since the 
sulphydryl group is sterically hindered, the rate of 
equilibration with other disulphides is low in 
comparison to for instance cysteine. A less rapid 
incorporation of D-penicillamine into disulphides in 
vivo presumably makes it more effective for therapeutic 
purposes (Friedman, 1977).
1.2.1. Absorption.
In man, oral doses of D-penicillamine are rapidly 
absorbed from the gut, peak serum concentrations 
occurring 2 - 3  hours after oral administration. The
21
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Fig- 1-2. Chemical Structures of Known 
Penicillamine Metabolites.
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serum peak concentration is directly dose related 
(Muijsers et al, 1984; Bergstrom et al, 1981; Butler et 
al, 1982).
Wass and Evered (1970), on the basis of in vitro 
studies with inverted sacs of rat intestine, suggested 
that D-penicillamine required a specific carrier for 
transport across the gut wall. The importance of an 
intermediate stage in the absorption of thiols, 
including D-penicillamine, has been demonstrated by 
Perret (1981). Using intestinal perfusion techniques, 
the luminal disappearance of D-penicillamine was shown 
to be far greater than that of its disulphide and 
comparable to that of other thiols such as cysteine and 
glycine. The high disappearance rate is thought to be 
due to the result of rapid binding, via disulphide 
bonds, to the proteins of the gut wall. Following the 
formation of the disulphide bridge, the D-penicillamine 
could then transfer into the portal blood stream. As 
thiols compounds can physically damage the gut mucosa, 
and that the gut experiences the highest concentration 
of D-penicillamine, this may explain the large 
incidence of gastrointestinal upsets.
Absorption of D-penicillamine is probably influenced by 
its binding not only to gut proteins but also to 
proteins present in food. Oxidation to the disulphide 
would also reduce uptake. Planas-Bohne (1972) reported
23
that fasting rats absorbed 25% more D-penicillamine 
than did animals given free access to food. Perret 
(1981) also found that rheumatoid patients absorbed, on 
average, 50% more of the drug in the fasting situation 
than when it was taken with food. Muijsers et al 
(1984) also claim that taking D-penicillamine 2 hours 
after dinner resulted in even lower absorption than 
when taken with food. They also speculate that 
concommitant iron therapy reduces the absorption of 
penicillamine, although earlier work by the same 
research group failed to show any effect of 
simultaneous supplementation of iron sulphate (525 
mg/day) on serum levels or renal excretion of the drug 
(van de Stadt et al, 1979). Schuna and coworkers (198 3) 
reported that although the systemic availability of 
D-penicillamine is reduced, the rate of absorption of 
the drug is not.
1.2.2. Distribution.
14 -In experiments using C-labelled D-penicillamine m
rats, a biphasic loss of plasma label occurred
(Patzchke and Wegner, 1977; Planas-Bohne, 1981) and
similar results have been obtained from studies which
measure total D-penicillamine in human volunteers,
showing a rapid elimination phase (half-life of about
1-5 hours) and a slower phase. Patzschke et al (1977b)
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reported the half-life of the second slower phase to be 
8 days, whilst Muijsers et al (1984) quote their 
findings of between 4-6 days.
The bi-phasic distribution profile shown by 
D-penicillamine would suggest the existence of two 
pools. The fast pool is thought to account for 
approximately 85% of the excretable D-penicillamine, 
whereas the slow pool is thought to be the reserve from 
which the serum pool is constantly refilled (van der 
Korst et al, 1981). Muijsers and coworkers (1984) 
report that the basal serum D-penicillamine levels 
gradually increase during prolonged therapy and slowly 
decrease upon termination of treatment. They 
tentatively suggest there may be a direct link between 
the slow onset of therapeutic effect of D-penicillamine 
in rheumatoid arthritis and the slow accumulation of a 
deep pool in the body. A possible location of this pool 
may be connective tissue. Animal studies of the 
distribution of labelled D-penicillamine show that the 
label is rapidly cleared from the liver and kidneys, 
but is cleared only slowly from collagen and elastin 
rich tissues, such as skin and bone (Patzschke and 
Wegner, 1977a) .
In his review of the metabolism of D-penicillamine, 
Perrett (1981) concluded that, in humans, 80% of the 
serum D-penicillamine is protein bound, about 12% in
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the disulphide forms and 6% is free penicillamine. The 
final 2% is probably in the form of metal complexes or 
as S-methylated D-penicillamine. However, these are the 
results mainly from studies on cystinuric patients and 
RA patients stabilised on D-penicillamine. Studies 
measuring free D-penicillamine levels after a single 
oral dose (Wiesner et al, 1981? Bergstrom et al, 1981) 
suggest that free D-penicillamine constitutes around 
25% of the total. The inherent reactivity of 
D-penicillamine may explain this apparent discrepancy, 
ie. as the drug enters the body approxomately 25% 
remains in the free form. However, as more drug enters 
the plasma and the longer it remains there, the more 
gets oxidised, causing a drop in the level of the free 
drug to a steady basal level, eg 6%.
Another possible explanation is the method of 
measurement of free drug. The acid precipitation method 
(Saetre and Rabenstein, 1978) was used to obtain a 
non-protein fraction in which to measure free drug. 
This assumes that D-penicillamine is protein-bound via 
covalent disulphide bridges, unaffected by acid 
treatment. However if a proportion is loosely ionically 
bound, this would be released and maintained in the 
free form by the acid pH, and subsequently measured as 
free drug.
The lack of an analytical system to measure individual
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metabolites has lead to some confusion as to which of 
the metabolites predominates. Most research groups so 
far have assumed that there is a mixture of 
penicillamine cysteine and penicillamine disulphide, 
the penicillamine cysteine predominating because of the 
low equilibrium constant for the formation of 
penicillamine disulphide (Jellum and Skrede, 1976). 
However, in a study by Kyogoku et al (1982) whereby 
they measured individual metabolites by the ninhydrin 
colorimetric method using an amino acid analyser, they 
reported that the main human metabolite was 
penicillamine-cysteine and that penicillamine 
disulphide was not detectable. In addition to this, 
they showed that species differences in metabolites 
occur. For instance, although the rat and dog show the 
same biphasic kinetic profile as man, both animals also 
have detectable levels of penicillamine disulphide.
The formation of disulphides is considered to be a 
dynamic process. In a short report by Miners (1984) he 
shows that measurable concentrations of penicillamine 
were present in plasma after intravenous and oral 
administration of both penicillamine cysteine and 
penicillamine disulphide to rats. This demonstrates the 
in vivo reduction of disulphide metabolites back to the 
parent drug. The enzyme(s) involved in this reduction 
are not known, but Miners (1984) suggests the 
involvement of glutathione reductase, thiol-disulphide 
transhydrogenases and nonspecific disulphide
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reductases. Moreover, although penicillamine is highly 
protein bound (mainly to serum albumin) it is not 
thought to be tightly bound and readily dissociates 
(Bergstrom et al, 1981b). In addition, the binding of 
D-penicillamine to serum proteins is not apparently 
dose related since higher doses of the drug lead to a 
decrease in percentage binding. This suggests the 
presence of a limited number of protein sites to which 
D-penicillamine can bind (van de Stadt et al, 1979). It 
is possible, therefore, that a dynamic equilibrium 
exists between free penicillamine, bound penicillamine 
and disulphide metabolites. This phenomena may be 
important if, as many believe, the active form of the 
drug is free penicillamine.
1.2.3. Excretion.
Studies by Perrett and his coworkers (1975) reported
that free D-penicillamine was not detected in the urine
or faeces of patients with rheumatoid arthritis or
cystinuria. Penicillamine disulphide was present in
both groups, whilst penicillamine cysteine was only
present in the urine. In addition, the urine contained
the only metabolically transformed metabolite,
S-methyl-D-penicillamine. The total recovery of the
drug in urine plus faeces, however, was less than 50%
of the administered dose. In a later study in which
14Perrett himself took D-(2- C )-penicillamine, 35%
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appeared in the faeces, which suggests bacterial
degradation of D-penicillamine before full intestinal
absorption could take place (Perrett, 1977). Another
theory for low recovery of D-penicillamine in urine and
faeces was proposed by van de Stadt et al (1979),
whereby the S-methyl-D-peniciilamine is oxidatively
deaminated by D-aminoacid oxidase, an enzyme active in
liver and kidney for the detoxification of
D-aminoacids. Although the possibility exists that
D-penicillamine may be enzymatically decarboxylated, a
study by Kucharczyk et al (1984) in which they measured 
14CO2 expiration from rats after an oral dose of
14C-D-penicillamine, reported that only 1.5% of the 
administered dose was expired. This indicates that the 
in vivo decarboxylation of the drug in rats may not be 
a significant metabolic pathway.
A further metabolite has been tentatively identified in 
the urine of patients with RA (Perret, 1981). Since 
homocysteine-cysteine disulphide is present in plasma 
and excreted in excess in cystinuria and Wilson's 
disease it is not an unreasonable supposition that 
homocysteine-penicillamine disulphide may be a 
penicillamine metabolite.
Patzschke et al (1977b), again using radiolabel studies 
in healthy volunteers, report 40% recovery of the label 
in the urine after oral dosing, and that the renal
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excretion rate was maximal shortly after intake of the 
drug and drastically declined within the first 12 
hours. Also the percentage of the drug that is excreted 
in the urine did not increase with dose or continued 
treatment suggesting that the "deep" pool is not easily 
saturated. Most studies agree that a total of 80% of 
the final dose detected in the urine is excreted in the 
first 12 hours.
The inability of most studies to detect free 
D-penicillamine in urine is probably due to the 
influence of urinary pH and incubation time (Carruthers 
et al, 1983). Hence any free thiol appearing in the 
bladder may be spontaneously oxidised to disulphides 
before excretion.
As yet no research group has been able to find a 
correlation between serum D-penicillamine levels and 
efficacy and/or toxicity. In a clinical trial 
undertaken by Munthe et al in 1979, it was found that 
the addition of cysteine to D-penicillamine treatment 
in non-responder RA patients raised the level of 
erythrocyte glutathione and, in some cases, turned 
non-resonders into responders. In relation to this, a 
preliminary report by van de Korst et al (1981) showed 
that a correlation existed between serum cysteine 
depletion and D-penicillamine induced side-effects.
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However, this has been somewhat invalidated by their 
more recent study on a larger group of patients 
(Muijsers et al, 1984).
A recent study (Emery et al, 1984) has tested the 
ability of RA patients on comparable doses of 
D-penicillamine to oxidise S-carboxymethyl L-cysteine 
(carbocysteine). Patients were classified as either 
poor "sulphoxidisers" or extensive "sulphoxidisers". 
There was a significant association between impaired 
sulphoxidation and manifestation of toxic side-effects 
to D-penicillamine. Although these workers point out 
the structural similarity between D-penicillamine and 
carbocysteine, the similarity between the latter and 
S-methyl D-penicillamine is more marked. If this is the 
metabolite responsible for toxicity, patients unable to 
oxidise it may produce side-effects. Should this be 
true, then increased levels of S-methyl D-penicillamine 
in the plasma might usefully predict the development of 
toxicity as would classification of the patient's 
sulphoxidation status.
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1.3. EXPERIMENTAL MODELS OF RHEUMATOID ARTHRITIS.
The development of a truly representative animal model 
of rheumatoid arthritis has been been seriously 
impaired by the inadequate knowledge of the aetiology 
and pathogenesis of the disease itself. Rheumatoid 
arthritis is an example of a chronic proliferative
synovitis of diarthroidial joints. Its pathogenesis 
cannot be readily assigned to an infectious, physical 
or metabolic stimulus. All other aspects, such as 
extra-articular manifestations or the presence of 
rheumatoid factor, are not essential for the existence 
of rheumatoid arthritis as a defined entity. To date 
there are no ideal models of rheumatoid arthritis and 
most other rheumatoid diseases of obscure aetiology. 
However, there have been several animal models
developed that bear some synergy with the human 
disease. The following is a brief overview of the most 
relevant models for rheumatoid arthritis.
1.3.1 Adjuvant Arthritis.
One of the most popular models of chronic,
immunologically mediated inflammation is the rat 
adjuvant arthritis (AA), a disease produced by the 
injection of Freund's complete adjuvant into certain
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dermal and subdermal tissue sites, usually the hind paw 
(Newbould, 1963). A local reaction develops 
immediately; a few days later the hind and forepaws 
swell and arthritic nodules appear on the ears and 
tail. This secondary reaction is termed "adjuvant 
disease" and is thought to represent a delayed 
hypersensitivity response to mycobacterial antigens 
(Pearson, 1956 and 1979).
AA can only be induced in rats and the increased 
susceptibility to the disease in certain strains of 
rats suggests that the condition probably has a 
genetic basis (Perlik and Zidek, 1973). Selective 
breeding for high or low responsiveness to adjuvant was 
used to derive two inbred strains of rats from a 
Wistar/Sprague-Dawley colony. Wistars were found to be 
entirely resistant to AA, whilst Sprague-Dawley rats 
were susceptible - the females affected severely 
compared to the males. In addition, AA is influenced by 
the age of the rat. Glenn and Gray (1965) found both 
young (< 21 days) and old (> 6 months) rats to be
relatively resistant to the disease.
As high as 95 - 100% successful induction of the
disease is attainable if the adjuvant is properly 
prepared, ie. by grinding the mycobacteria in a pestle 
and mortar before preparing the suspension (Swingle, 
1974). The intradermal route is commonly used and is
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most effective when given in the foot pad or tail 
(Glenn and Gray, 1965). The volume and concentration of 
injected material are important. At least 0.1 mg whole 
bacteria in a volume of 0.05 - 0.1 ml is necessary to 
induce AA by foot pad or tail or tail administration. 
Due to their high susceptibility to the adjuvant, 
female Sprague-Dawley rats in the age range 6 to 8 
weeks are chosen for experiments.
Although this animal model for rheumatoid arthritis is 
not ideal, there are some striking clinical and 
pathological similarities between AA and RA. These are 
summarized in Table 4. Other laboratory findings of AA 
which resemble RA include anaemia, decreased serum 
iron, decreased rate of incorporation of iron into red 
cells (Mikolajew et al, 1969) and elevation of 
erythrocyte sedimentation rate, serum glycoproteins and 
copper (Gralla and Wiseman, 1968; Weimer et al, 1968). 
Rheumatoid factor and antinuclear antibodies, detected 
in RA, however, have not been reported in AA. Depressed 
levels of hepatic aminopyrine demethylase and of 
cytochrome P450, observed in RA, have also been 
reported in AA (Cawthorne et al, 1976) and may be 
associated with altered drug metabolism by the liver.
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Clinical AA
Acute and, recurrent arthritis ++
Peripheral joints
Chronic deforming arthritis ++
Eye lesions +
Progressive and destructive ++
joint disease
Pathological
Acute and subacute synovitis ++
Primarily mononuclear cell ++
response
Invasion of bone and joint ++
space by pannus

















Table 4. Comparison of AA and RA (from 
Pearson, 1979 ) .
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1.3.2 Collagen-Induced Arthritis in Rats.
Antibodies to collagen have been detected in the sera 
and the synovial fluid of rheumatoid patients (Steffen 
et al, 1974; Huffstutter et al, 1980} suggesting that 
autoimmunity to collagen may contribute, at least in 
part, to the disease process. Following these 
observations, studies by Trentham et al (1977) have 
shown that immunization of rats with type II collagen 
(the type found predominantly in cartilage) results in 
an inflammatory polyarthritis 10 - 16 days after
immunization in approximately 40% of the animals. 
Collagen antibody titres in the sera of rats with 
polyarthritis were, in general, higher than in the sera 
of immunized but nonarthritic rats. Thus like human RA, 
the polyarthritis in the collagen model may be related 
in some way to collagen autoimmunity. Pathological 
changes in the rats of collagen-induced arthritis are 
simmilar to the acute phase of human RA: there is
tenosynovitis, with polymorphonuclear leukocytes and 
mononuclear cells invading the joint space, and erosion 
of cartilage from the articular side with relative 
sparing of the bone. There are, however important 
differences between rheumatoid arthritis and collagen 
arthritis. Unlike RA, collagen arthritis does ot occur 
spontaneously, it is not self-perpetuating and 
invariably subsides several weeks after onset.
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Fluctuating remissions and exacerbations do not occur 
and the hallmark extraarticular lesions of RA (ie. 
subcutaneous nodules, serositis and vasculitis) are 
absent. Also, the variety of abnormal antibody 
responses associated with RA i.e. rheumatoid factors 
and antinuclear antibodies, have not been demonstrated 
(Trentham, 19 8 2).
The most susceptible rats to collagen induced arthritis 
are Wistar rats aged between 4 and 5 weeks, and the 
expression of the disease is not influenced by the sex 
of the animal. The incidence and severity of the 
disease increases as the amount of collagen injected is 
increased (Trentham et al, 1977).
Although collagen induced arthritis is a versatile 
system with some advantages over other models of 
arthritis, it suffers from the inability to produce a 
consistant response in the majority of test animals. 
Moreover, the appearance of arthritis in immunized rats 
has been reported to be affected by psychological 
stress. Immunized rats exposed to a caged cat developed 
cell-mediated immune responses and antibodies to 
collagen, but arthritis appeared in only 3% of animals 
in the stressed group (Sloboda et al, 1981).
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1.3.3. Antigen-Induced Arthritis In Rabbits.
A chronic synovitis, closely resembling human RA with 
regard to histopathology and chronicity, can be 
produced in rabbits by an initial systemic immunization 
followed by injection of the same antigen into a knee 
joint (Cooke and Jasin, 1972). This method of induction 
of arthritis is based on earlier observations of 
Dumonde and Glynn (19 62) on fibrin-induced arthritis. 
The ensuing antigen-induced arthritis affecting the 
knee required the presence of antigen in the initial 
immunization, the development of delayed 
hypersensitivity, and high titre of circulating 
antibodies to the inducing antigen (Consden et al, 
1971). Ovalbumin and bovine serum albumin have been the 
the most extensively used antigens in this model of 
chronic inflammation. Besides rabbits, the disease can 
be induced in guinea-pigs (Dumonde et al, 1977), mice 
(Brackertz et al, 1977), and chickens (Oates et al, 
1973) .
The development of the disease is strain-dependent and 
genetically related (Blackham et al, 1974). The animals 
are immunized by two subcutaneous injections of the 
antigen in Freund's complete adjuvant, and challenged 6 
weeks later by intra-articular injection of the antigen 
into the knee joint, after the existence of delayed 
hypersensitivity to the antigen had been established by
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skin testing. The rabbits produce an arthritic response 
in the antigen-injected joint. This continues through 
an acute phase into a chronic phase (115 days after 
intra-articular injection) as judged by the presence of 
villous hyperplasia of the synovial membrane, pannus, 
lymphocyte and plasma cell infiltration and bone and 
cartilage erosions (Hunneyball et al, .1978).
Antigen induced arthritis provides a model of arthritis 
that not only closely resembles RA at both the 
macroscopic and histological levels, but in its pattern 
of responsiveness to antirheumatic drugs is also very 
similar to that of RA. However, the use of this model 
for pharmacological screening is limited due to the 
size of the animal and the duration of treatment 
required to demonstrate activity with disease modifying 
compounds , particularly those of the slow-acting type 
such as D-Penicillamine.
1.3.4 The Effects of D-Penici11amine in Experimental 
Models of Arthritis.
D-Penicillamine is neither analgesic nor 
anti-inflammatoryiin as much as it fails to inhibit 
acute experimental inflammations that are suppressed by 
the aspirin-like, non-steroidal anti-inflammatory 
(NSAID) drugs (Arrigoni-Martelli, 1979). This implies a
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lack of influence on pharmacological mediators of 
inflammation and a quite different mode of action from 
that of the NSAID's.
Whereas the adjuvant arthritis model is considered to 
be successful for the screening of potentially new 
NSAID's, slow acting drugs such as penicillamine, 
levamisole and chloroquine have little effect on the 
disease. Early studies by Klamer et al (1968) reported 
a moderate inhibition of AA with the racemate 
D,L-penicillamine. Later studies by Liyanage and Currey 
(1972) did not observe any effect when D-penici11amine 
was administered at the dose 200 mg/kg orally, from a 
few days prior to the adjuvant injection to 20 days 
later. Worstmann and Kretzchmar (1975) reported an 
inhibitory effect with the very high dose of 464 mg/kg. 
In his experiments, Arrigoni-Martelli (1979) observed 
that 50 mg/kg of D-penicillamine given to rats with 
already developed adjuvant arthritis or from the day of 
adjuvant injection to 28 days later enhanced the 
severity of the syndrome. No effect was observed when a 
similar dose was administered for a few days prior to 
and immediately after the adjuvant injection.
The effect of D-penicillamine in the established model 
of collagen arthritis is similar to clinical 
observations in human rheumatoid arthritis. From X-ray 
analysis, Sloboda et al (1981) showed that rats with
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the established lesion of collagen polyarthritis had 
decreased joint destruction on treatment with a daily 
oral dose of 200mg/kg D-penicillamine, treatment 
commencing the same day as the animal was immunized 
with type II collagen. However, the decrease in joint 
destruction occurred in the absence of an 
anti-inflammatory effect. The authors stress the 
importance of radiographic evaluation of the efficacy 
of the drugs being studied in this model, a criteria 
not always acceptable for routine drug screening.
As stated previously, the rabbit model of antigen 
induced arthritis is probably the most closely 
correlated model to the human disease. Hunneyball et al 
(1978) used this model to study the effects of 
D-penicillamine on the immune response and development 
of the disease. In these experiments, they managed to 
show diminution of the arthritis after daily oral 
administration of D-penicillamine at doses equivalent 
to that usually administered to rheumatoid patients 
(ie. 10 - 15 mg/kg body weight). With D-penicillamine 
treatment beginning 16 weeks after the onset of chronic 
monoarticular arthritis, the severity of the chronic 
synovitis was reduced in a considerable proportion of 
the animals. This was reflected in a reduction in joint 
circumference beginning 40 - 50 days after initiation 
of treatment, and this parallels the delay observed in 
rheumatoid patients between the initiation of treatment
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and the onset of effect. When D-penicillamine therapy 
was initiated prior to immunization, a greater 
reduction in joint swelling, histopathology and 
macroscopic score was obtained (Hunneyball et al, 
1979 ) .
1.4 SCOPE OF THE STUDY.
The aim of this project was to examine the metabolism 
of D-penicillamine in an experimental model of 
arthritis and a healthy control in order to expose any 
fundamental differences which may help explain the mode 
of action (therapeutic or toxicological) of the drug. 
As reviewed in the previous section, all the available 
animal models have their pros and cons. For metabolic 
purposes, rat adjuvant arthritis was considered to be 
the most suitable representation of the disease, having 
taken into account the practical constraints imposed. 
It is easily induced, with the arthritis developing to 
a uniform degree in the majority of the innoculated 
animals. In addition, the progression of the disease 
can be monitored without the need for sophisticated 
techniques. Also, prolonged drug therapy is avoided, 
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2.3. SYNTHESIS OF L-CYSTEINE-D-PENICILLAMINE MIXED 
DISULPHIDE.
The following is an adaptation of the method originally 
described by Crawhall et al (1964).
Free base L-cysteine (51.43g, 0.48mole) and
D-Penicillamine hydrochloride (16.71g, 0.09 mole) were 
dissolved in ammonium hydroxide (1000 ml, 4 mole) in a 
Buchner flask, to which ferric chloride (10 ml, 5% w/v 
in water) was added. Air was drawn through the solution 
for 24 hours via a wash bottle containing ammonium 
hydroxide (500 ml, 4N). The precipitated cystine and 
ferric hydroxide were allowed to settle out from the 
mixture. The supernatant was removed by suction and 
evaporated to dryness at 65-70°C (bath temperature). 
This crude disulphide was washed with cold water (2L) 
and filtered to remove insoluble material.
Amberlite CG120 (Na) (423g) was converted to the H+form 
by washing and stirring in a large beaker for a total 
of 2-3 hours with portions of HCL (IN) (7.5L). After 
decanting the acid the residual resin was washed free 
of Cl with portions of deionized water (4x3L).
The combined crude disulphide washings were added to 









Fig. 2.1. NMR Identification of Penicillamine 
Cysteine.
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for eventual abscence of amino acid from solution ( 2 
drops of solution on TLC plates and 2 drops 5% 
ninhydrin in EtOH to give a purple colour on heating to 
110°C if any amino acid remains). The resin was washed 
by stirring with water (4xlL) until Cl ions were no 
longer detectable with AgNO^. After decanting the water 
the resin was stirred with ammonium hydroxide (2N, 
4.5L) in 1L portions and the combined filtered eluates 
evaporated to dryness leaving a light yellow solid 
(20g) of mixed disulphide as identified by NMR (see 
Fig. 2.1). Contamination with penicillamine disulphide 
and cystine was 6.3% and 7.7% respectively.
2.4 ANIMALS
All animals used were female, Sprague-Dawley rats bred 
in the Bath University Animal House. Weights at the 
starting date of any experiment were between 120-160g.
2.4.1 Dosing.
All rats that were to be orally dosed were starved the 
previous night and for 3 hours after dosing to ensure 
maximal absorption of the drug. Subsequently, they were 
allowed food and water ad libitum. Drugs for 
intravenous dosing were made up in 0.9% saline. Drugs 
for oral dosing were made up in a solution of 5 mis
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tween 80 (1%) in 100 mis Carboxy methyl cellulose
(0.5%).
2.4.2 Urine Collection.
Urine was collected from animals housed in individual 
metabowls. Food and water were allowed ad libitum and 
animals were kept in the metabowls for a maximum of 24 
hours.
2.4.3 Serum Collection.
Rats were initially anaesthetized in ether and blood 
withdrawn by cardiac puncture into vials containing no 
anticoagulant. Vials were left at room temperature for 
at least 15 minutes then spun at 3000 rpm for 10 mins. 
Serum was removed into sterile vials and stored at 
-20°C until use.
2.4.4 Cannulations.
Rats were anaesthetized with hypnorm/midazolam. 
■^C-D-penici11amine (10 pCi; 200mg/kg) was introduced
into the rat via a cannula in the right jugular vein. 
Serial blood samples (0.3 ml) were removed via a 
cannula in the left carotid artery into Eppendorf vials 
containing EDTA. Blood volume was replaced throughout 
the experiment with saline. The animal was kept warm by
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a thermal blanket maintained at 37°C. Adjuvant 
arthritic rats were used on Day 15 of the course.
2.4.5 Induction of Arthritis
Polyarthritis was induced by a single injection into 
the right hind paw of 0.0 5 mis of a 2.5 mg/ml solution 
of mycobacterium Tuberculosis in liquid paraffin. The 
mycobacterium was ground in a pestle and mortar and was 
stored reground for at least 1 month before use. The 
day of injection of the adjuvant is designated Day 0.
Rats in the treatment group received the test drug from 
Day -1 to Day 17. Normal control rats received 
equivalent volumes of vehicle.
Animals were housed in cages of 3 throughout the 
adjuvant course.
2.4.6 Evaluation of Arthritis
The following parameters were used to assess the 
severity of the arthritis:
i) Weight change (Winder et al, 1969). Changes in body 
weight and retardation in weight gain throughout the 18 
day adjuvant course were used to monitor the course of 
the disease and the response to drug treatment.
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ii) Paw volume. Initially right hind paw volume was 
measured by mercury volume displacement as the paw was 
dipped as far as the ankle into a small bath of
mercury. The displacement of the mercury was monitored 
by a pressure transducer linked to digital readout 
calibrated on a linear scale of 1-10. As the disease 
began to spread, the left hind paw volume was also 
measured from Day 9 onwards.
iii) Severity of arthritic lesions (Currey and Ziff,
1968). This was based on the degree of joint movement
in the four paws. Severity of arthritic lesions was 
graded using a scoring system of 1 = minor, 2 =
moderate, 3 = severe for each paw, thus a maximum score 
of 12 may be obtained.
2.5. BIOCHEMICAL MEASUREMENTS
2.5.1 Protein Concentration - Folin Assay.
(As described by Lowry et al, 1951).
The following solutions were prepared:
a) 5% w/v CuSO^.5H2O
b) 10% W/v NaK Tartrate
c) 2% w/v ^ 2 ^ 2  in O.lM NaOH
d) 1 vol. Folin - Ciocalteau reagent plus 2 vols. 
distilled water
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e) 1 ml of a) + 1 ml b) + 8 ml H^0
f) 1 ml of e) + 50 ml c)
Solutions e) and f) were prepared immediately before 
use.
Incubations were set up in duplicate.' 0.4 ml sample 
was added to 4.0 ml solution f) and 0.4 ml solution d). 
Tubes were whirlimixed and left to stand for 30 mins in 
the dark at room temperature. The absorbance at 650 nm 
was read against a reagent blank. Protein 
concentrations were calculated from a calibration curve 
prepared using bovine serum albumin in saline as 
standard to a maximum concentration of 4 00 ug/ml. 
Samples with a protein concentration higher than this 
were diluted as appropriate with saline.
2.5.2 Urinary Creatinine Concentrations
The following stock solutions were prepared:
a) 35mM Picric acid
b) 1.6M NaOH
c) 1.2M TCA
Urine samples were diluted 1 in 50 with distilled 
0.5 ml of diluted sample was pipetted into a test tube
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to which 0.5 ml TCA solution and 1 ml picric acid : 
NaOH (1:1) solution was added. The tubes were 
whirlimixed and incubated for 20 mins in a water bath 
maintained at 25°C. Absorbance was measured against a 
water blank, treated as above, at 490 nm with the 
spectrophotometer block maintained at 25°C. Creatinine 
concentrations were calculated from a calibration curve 
prepared from creatinine standards in the range 0.1 to
5.0 mg/dl.
2.5.3 Serum and Urinary Copper Concentrations
Serum and urine samples were diluted 1 in 10 with 
deionized, double distilled water. Copper levels were 
measured on an SP9 Automatic Absorption 
Spectrophotometer, previously calibrated with solutions 
of known copper concentrations.
2.5.4 Serum and Urinary Sulphydryl Levels.
The following stock solutions were prepared:
a) 0.1M phosphate buffer pH 7.4
b) 0.8 mg/ml DTNB in 0.1M phosphate buffer made up 
immediately before use and stored in a dark brown 
bottle.
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c) ImM glutathione in 0.1M phosphate buffer.
i) Serum.
0.05 ml serum was pipetted into a 1 ml cuvette to which 
0.75 ml 0.1M phosphate buffer and 0.2 ml DTNB were 
added. Cuvettes were whirlimixed and incubated for 5 
mins. at 37°C. Absorbance was measured at 440 nm 
against a blank of 0.05 ml serum plus 0.95 ml 0. 1M 
phosphate buffer with the spectrophotometer block 
heater maintained at 37°C.
ii) Urine.
0.5 ml urine was pipetted into a 1 ml cuvette to which 
0.3 ml 0. 1M phosphate buffer and 0.2 ml DTNB were 
added. Cuvettes were whirlimixed and incubated for 5 
mins at 37°C. Absorbance was measured at 440 nm against 
a blank of 0.5 ml urine plus 0.5 ml 0. 1M phosphate 
buffer with the spectrophotometer block heater 
maintained at 37°C.
Calibration curves were constructed using glutathione 
solutions of known concentrations (not exceeding ImM). 
Absorbance of standards (treated as for serum samples) 
were read against a blank of 0.05 ml ImM glutathione 
plus 0.95 ml 0.1M phosphate buffer.
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When calculating urinary sulphydryl levels a 
multiplication factor of 0.1 must be used to account 
for the ten-fold increase in sample volume to standard 
volume.
2.6. THIN LAYER CHROMATOGRAPHY
The following system was employed to separate and 




7% Water, deionized,double distilled 
3% 6M Acetic acid
Stationary phase:
TLC aluminium sheets coated with silica 
gel 60 (without fluorescent indicator),
0.2 mm thick (E.Merck, Darmstadt, Germany
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Amino Acid Visualisation:
0.3g ninhydrin in 100 ml butan-l-ol plus 
3 ml glacial acetic acid.
After running in the above mobile phase, TLC plates 
were completely dried, then sprayed with the ninhydrin 
solution and heated to 110°C in a small oven. Amino 
acids appeared as small purple spots from which Rf 
values were calculated.
In radiolabelled-TLC studies, TLC plates were divided 
into 0.5 cm strips horizontally, and the silica gel 
scraped off into seperate insert vials to which 4.5 mis 
Optiphase scintillation fluid was added. Vials were 
whirlimixed and radioactivity measured.
2.7 D-PENICILLAMINE DETERMINATION BY HPLC.
The measurement of D-Penicillamine by HPLC employed an 
elaborate two column system coupled to a gold-mercury 
electro-chemical detector. This was a modification of 
the method initially described by Abounassif and 
Jefferies (1983). This system allowed unwanted 
interfering plasma peaks, the majority of which elute 
before the penicillamine peak, to be diverted away from
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the detector but allowed the penicillamine to pass to 
the detector. Thus, this protected the sensitive 
electrode from "coating" by plasma compounds and 
prevented a loss in electrode sensitivity.
The overall configuration of the system is shematically 
represented in Fig. 2.2.
HPLC Equipment
Constant flow pumps (Consta Metric III pumps, L.D.C. 
Ltd., Stone, Staffs, UK) were fitted with additional 
custom-made pulse dampers to maximise a pulse-free 
solvent flow. Samples were introduced by means of a 
high-pressure injection valve fitted with a constant 
volume loop (0.1 ml) (Rheodyne 7125, Rheodyne Ltd., 
Cotati, California, USA). All column fittings, tubing 
and plumbing were supplied by HETP Ltd., Macclesfield, 
UK.
Switching of the solvent flow was achieved by means of 
a high-pressure switching valve (Rheodyne 7000, 
Rheodyne Ltd.)
The column system was maintained at 37°C by a heated 





( i i )
A = Rheodyne injection valve 
B = Rheodyne switching valve
PC = pre-column 
AC = analytical column 
W = waste
Fig. 2.2. Column arrangement and port positions 
for switching system.
(i) Loading pre-column and flushing to waste
(ii) Transfer from pre-column to analytical 
column.
58
The column eluent was monitored by passing it through 
the flow-cell of an electrochemical detector (BAS 
LC-4A, Bioanalytical systems, West Lafayette, USA) 
fitted with a thin-layer cell containing a gold-mercury 
electrode (BAS, TL-6A). The reference electrode was an 
Ag/AgCl electrode (RE-1).
The detector output was recorded on a potentiometric 
chart recorder (JJ CR650S recorder, JJ Ltd., 
Southampton, UK).
Mobile Phase
HPLC grade methanol and deionized water were used to 
make up mobile phases to minimize contamination. The 
mobile phase used in all systems for measuring 
penicillamine in biological fluids consisted of 0.05M
-■3
citrate buffer (pH 3.2), 4% (v/v) methanol, 5 x 10 M
sodium dodecyl sulphate and 0.1 g/1 EDTA. All mobile 
phases were freshly prepared and filtered using 0.45 urn 
filters (Type HA, Micropore filters, Millipore Ltd., 
Harrow, Middlesex, U.K.) Mobile phase pH was checked 
using a Howe 6031 pH meter, V.A. Howe Ltd, London, UK).
After filtration mobile phases were degassed under 
vacuum exceeding 500 mmHg for 20 mins. The degassed 
condition was maintained by a Du-Pont flotation
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degassing system which is effective for at least 24 
hours.
2.7.1 Total D-Penici11amine in Serum.
Calibration Curve.
Stock solutions of D-Penicillamine in mobile phase
containing 1 g/L EDTA were used to prepare standards in
serum in the range 5 mg/L (0.335 x 10 M^) to 250 mg/L 
-3(1 .667 x 10 M) . 0.1 ml aliquots of the appropriate
D-penicillamine solution in mobile phase were added 
into aliquots of 0.9 mis. blank serum. The "spiked" 
serum samples were then treated as for test samples as 
described below. Calibration curves (Fig. 2.3) were 
repeated before each assay batch along with a 10 pg/ml 
D-penicillamine standard throughout the assay. The 
coefficient of variation was less than 3% throughout 
the day.
Sample Treatment.
1 ml of sample/standard was pipetted into glass flow 
tubes to which 0.72 ml of dithiothreitol (20 mg/ml) was 
added, followed by 1.28 ml of disodium hydrogen 
phosphate buffer (0.05M) to give a final volume of 3 
mis. The tubes were thoroughly whirlimixed and
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incubated in a water bath maintained at 60°C for 3 
hours. Upon removal from the water bath, the tubes were 
again thoroughly whirlimixed and the tubes then spun at 
4,500 rpm for 25 mins. in a Hettich Universal 
Centrifuge (Arthur Horwell ltd., London U.K:). The 
supernatants were removed and pippetted into microfuge 
tubes (Sterilin Ltd., Feltham, Middlesex, U.K.) which 
were then spun in an Eppendorf microfuge at maximum
speed for 1 minute to further remove any debris. The
supernatants were then filtered through Amicon 
microfilters (0.2 urn pore size, type YMT, Amicon Ltd., 
Stonehouse, Gloustershire, U.K.). The filtrates were 
then added to an equal volume of mobile phase 
containing 1 g/L EDTA in small sample tubes (TSP1/2, 
Fisons Ltd., Loughborough, UK). 0.1 ml of sample was 
injected onto a precolumn (15 cm Spherisorb-NH^, 5 urn, 
pump flow rate 1.45 ml/min.) whose outlet flushed to 
waste, by means of the injection valve. At 7.5 minutes 
precisely, the running sample was transferred to the 
main analytical (5 cm, Spherisorb-NH^, 5 urn, pump flow
rate 1.35 ml/min.) by means of the swithching valve.
The eluate then flowed directly to the detector whose 
electrode was maintained an an applied potential of 
0.15V. After elution of the penicillamine peak the flow 
was switched back using this valve so that the next 
sample could be introduced onto the precolumn. All 
samples were maintained at 4°C before measurement and 
were injected in duplicate, in the order standard,
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sample no.l (duplicated), sample no.2 (duplicated), 
standard, and so on. Concentrations of total 
D-Penicillamine in unknown serum samples were 
calculated from the standard curve. A typical
chromatogram from the sera of D-penicillamine treated 
rats, showing the injection order is illustrated in 
Fig. 2.4.
2.7.2 Total D-Penicillamine in Urine.
Determination of total D-Penicillamine in urine was
performed as above except on a one-tenth scale, ie 
incubations consisted of 0.1 ml sample (or standard), 
0.072 ml dithiothreitol (20 mg/ml) plus 0.128 ml 
disodium hydrogen phosphate buffer (0.05M) to give a 
final volume of 0.3 ml. After the three hour incubation 
at 60°C, tubes were removed straight onto ice and 0.2 
ml of mobile phase containing 1 g/L EDTA was added. 
Sample injections and valve switching times were as 
above. Fig. 2.5 shows a representative calibration
curve.
2.7.3 Free D-Penicillamine in Serum
Blood for free D-penicillamine determinations was




50 100 150 S00 250 (jg/nl
Fig. 2.3. Calibration curve for total
D-penicillamine in rat serum, 
(r > 0.99)
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Fig. 2.4 Typical chromatogram for total
D-penicillamine in rat serum. Spiked 
standard samples corresponding to 











200 300 480 SO0
Fig. 2.5. Calibration curve for total
D-penicillamine in rat urine, 
(r > 0.99)
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rpm for 10 mins. the supernatant (1 ml) was transferred 
to an Amicon filtration unit. Units were spun for 25 
mins. at 4,500 rpm. The resulting ultrafiltrate was 
then mixed 1:1 with mobile phase (containing 1 g/L 
EDTA) and maintained at 4°C until assayed as above. 
Calibration curves were prepared from "spiked" 
ultrafiltrate.
Statistical Analysis
The Student's "t" test was routinely used as the data 
was assumed to be normally distributed. The level of 





3.1 ESTABLISHMENT OF A NON-TOXIC DOSE OF 
D-PENICILLAMINE
In recent years there have been a number of reports 
suggesting a genetic predisposition to toxic reactions 
induced by D-penicilfamine therapy in humans (Panayi, 
1978; Wooley 1980, Perrier, 1985). Similar studies in 
rats have highlighted strain variabilities in toxicity 
to the drug. Donker and co-workers (Donker et al 1984) 
showed that whilst Lewis and Sprague-Dawley rats, 
weighing between 120-150g, tolerated a daily oral dose 
of 2 0 or 5 0 mgs of d-penicillamine for 5 months, Brown 
Norway rats developed severe side effects after 3-8 
weeks at the same dose. Subsequent experiments required 
the administration of D-penicillamine to female Sprague 
Dawley rats acutely and throughout the period of an 
adjuvant course. Therefore preliminary experiments were 
performed to establish a dose of D-penicillamine that 
could be admnistered both acutely and daily throughout 
the adjuvant time course, without inducing toxic side 
effects. A range of biochemical parameters likely to 
be affected by D-penicillamine were therefore monitored 
to assess potential toxicological effects.
Proteinuria is one of the most commonly observed side 
effects of D-penicillamine treatment in man, presumably 
caused by renal damage. Urinary protein was therefore 
measured as an indicator of the efficiency of
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glomerular filtration and renal damage. However as 
disturbances in glomerular filtration are not always 
accompanied by proteinuria (Rickers et al, 1980),
urinary creatinine excretion was also monitored. 
Assuming there is no change in plasma creatinine, an 
increase of urinary creatinine would be an indicator of 
renal function.
Serum sulphydryl levels are known to be reduced in both 
rheumatoid arthritis and adjuvant arthritis (Lorber et 
al, 1964; Butler et al, 1969). Given the capacity of 
D-penicillamine to take part in disulphide exchange 
reactions gross changes in serum and urinary 
sulphydryls would be expected to reflect any acute 
toxicological effects of D-penicillamine.
Metal chelation by D-penicillamine, particularly 
copper, could also result in toxicological 
manifestations such as neutropenia. As copper is 
extensively chelated by D-penicillamine copper levels 
in serum and urine were monitored to ensure that 
exhaustive depletion did not occur. Increases in 
copper excretion also served to verify that 
D-penicillamine at the doses employed was 
"pharmacologically" active.
In addition to the above parameters, changes in the 
body weight of the animals was monitored as this is
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often a useful reflection of the well-being of the 
animal.
3.1.1. Acute Dosing with D-Penicillamine.
Preliminary experiments involved acute oral dosing of 
D-penicillamne at three selected doses. Biochemical 
parameters were compared with controls receiving 
vehicle only. Female Sprague-Dawley rats weighing 
between 120-160g were treated with a single, oral dose 
of D-penicillamine at dose levels of 100, 200 and 400 
mg/kg (4 rats per dosage group). Urine was collected 
over the subsequent 2 4 hours, from which urinary 
protein, creatinine, sulphydryl and copper excretions 
were measured. Blood was also collected at the end of 
the 24 hour period and assayed for serum copper and 
sulphydryls by the methods described in Section 2.5.
Figs 3.1.1 (a) and (b) show the effect of a single oral 
dose of 100, 200 or 400 mg/kg of D-penicillamine on
urinary excretion of protein and creatinine 
respectively, over the subsequent 24 hours post-dosing. 
Whilst the two lower doses showed no significant 
difference from controls given only the vehicle, 
animals treated with 400mg/kg D-penicillamine showed a 
significant increase in protein excretion, 121.9 +13.8 
mg/24 hr as compared to 48.4 + 4.9 mg/24 hr for control 
rats (p<0.01). Similarly, urinary creatinine was
70
(a)
( b )  /
F i g .  3.





•  • •  p  <  0 - 0  1 
• • P < 0 02
100 200 4 0 0  ng/kg
.1. Excretion of (a) Protein and (b) Creatinine 
in rat urine in the 24 hours after a single 
oral dose of 100, 200 or 400 mg/kg 
D-Penicillamine (n=4, mean + S.E.M.)
71
significantly increased at the 400 mg/kg dose with 
excretion being 7.6 + 0.8 mg/24 hr, compared to 4.3 +
0.2 mg/24 hr (p<0.02) in vehicle only animals.
As shown in Fig. 3.1.2 (a) serum sulphydryl levels were 
not significantly (p>0.05) affected by D-penicillamine 
at any dose studied, whereas a dose related increase in 
urinary sulphydryl excretion (Fig. 3.1.2 (b) ) was
apparent. A dose of 200 mg/kg D-penicillamine resulted 
in urinary SH levels of 57.0 + 1.2 jig/24 hr compared to
41.1 + 4.8 }ig/24 hr in control animals (p<0.05).
Urinary SH excretion was 83.2 + 6.7 mg/24 hr after an 
oral dose of 400 mg/kg D-penicillamine (p<0.02).
Increasing doses of D-penicillamine caused a 
corresponding dose related significant increase in 
urinary copper excretion, as shown in Fig. 3.1.3 (b) .
Whilst control values were only 6.5 + 0.7 *ig of copper 
excreted in 24 hours, doses of 200 mg/kg increased 
output to 20.4 + 2.1 jag/ 24 hr (p<0.01). Urinary copper 
excretion was 34.1 + 4.8 ug/24 hr after an oral dose of 
400 mg/kg D-penicillamine (p<0.001). However, Fig.
3.1.2 (a) shows that serum copper levels were not
significantly different from the control value of 0.98 
+0.1 ug/ml at any of the three dosage levels.
These results indicate that at a dose of 200 mg/kg the 
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in the 24 hours after a single oral 
dose of 100, 200 or 400 mg/kg 
D-Penicillamine (n=4, mean + S.E.M.)
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F i g .  3 . 1 . 3 .  Copper levels in (a) serum (b) urine 
in the 24 hours after a single oral 
dose of 100, 200 or 400 mg/kg 
D-Penicillamine (n=4, mean + S.E.M.)
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the parameters monitored, whereas at 4 00 mg/kg toxic 
effects are observed. This is particuarly manifest in 
values for urinary protein and creatinine excretion 
(Figs. 3.1.1 (a) and (b) ) with only the highest dose
significantly affecting these parameters, suggesting an 
immediate interference with renal function at this 
dose.
From these results it would seem that the maximum 
"safe" dose of D-penicillamine that can be 
administered without toxic effects is 200 mg/kg.
3.1.2 Chronic Dosing with D-Penicillamine.
Having established that an acute dose of 200 mg/kg of 
D-penicillamine could be tolerated with no apparent 
side effects, the next step was to ensure that chronic 
treatment with this dose of the drug could also be 
tolerated with no untoward effects. D-penicillamine 
was administered orally at a dose of 200 mg/kg for 18 
days. The same biochemical parameters as measured 
previously were monitored on days 1, 3, 7, 9, 15 and 17 
after dosing commenced (4 rats per day group). This 
time period covers the length of the adjuvant course 
employed.
Figs 3.1.4 (a) and (b) show the effect of the selected 
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Fig. 3.1.4. Urinary excretion profile of (a) protein 
and (b) creatinine from control rats 
and rats treated daily from day 0 with 
D-penicillamine (200mg/kg p.o)
(n = 4 + S.E.M.)
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the 18 day period. Urinary protein increased from 62.0 
+ 10.1 mg/24 hr to 104.9 + 12.6 mg/24 hr in control 
rats over the 18 day time course as the animals grew 
and matured. This pattern was not significantly altered 
by chronic D-penicillamine treatment (200 mg/kg), 
urinary protein increasing from 80.2 + 11.2 mg/24 hr on 
day 1 to 102.3 + 10.2 mg/24 hr at the end of the
course. Urinary creatinine levels increased from 4.1 +
1.1 mg/24 hr to 5.7 + 0.5 mg/24 hr in control rats 
during the 18 days. This was paralleled by an increase 
(not significantly different from control) from 4.2 +
0.9 mg/24 hr to 6.1 + 0.6 mg/24 hr in the rats treated 
with 200 mg/kg D-penicillamine.
Fig 3.1.5 (a) shows that serum sulphydryl levels did
not significantly change throughout the 18 days 
remaining at around 50 pg/ml. D-penicillamine treated 
rats were not significantly different from controls 
during the 18 days. Fig 3.1.5 (b) shows that urinary SH 
excretion was significantly higher after the first day 
of D-penicillamine treatment, 41.2 + 4.6 ug/24 hr in 
control rats, compared to 64.0 +4.8 pg/24 hr in the 
animals dosed with 200 mg/kg of the drug (p<0.05). 
However, on repeated daily dosing with D-penicillamine, 
total free SH goups in the urine showed no significant 
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Fig. 3.1.5. Sulphydryl levels in (a) serum and
(b) urine from control rats and rats 
treated daily from day 0 with 
D-penicillamine (200mg/kg p.o)
(n = 4 + S.E.M.)
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The most drammatic effects of the drug were on the 
urinary copper profile (Fig 3.1.6 (b)). Copper
excretion increased rapidly from a control value of 5.0 
+ 0.3 pg/24 hr to a maximum of 30.4 + 4.9 jig/24 hr at 
day 9 (p<0.001). Thereafter urinary copper excretion
declined to 19.5 + 1.8 pg/24 hr on day 17, but this was 
still significantly higher than control values 
(p<0.0 01). Serum copper levels however (Fig. 3.1.6 
(a)), were unaffected by the drug treatment during the 
18 days, remaining between 1.1-1.2 pg/ml in both 
groups.
As Fig 3.1.7 shows, both control and D-penicillamine 
treated rats grew rapidly during the 18 days, 
increasing in weight by 71.2 + 1. 2g and 72.4 + 1. 8g 
respectively (p>0.05).
The present results thus show that a dose of 200mg/kg 
D-penicillamine can be safely administered on a daily 
oral basis to young, female Sprague-Dawley rats over an 
18 day period with no apparent adverse effects. Having 
established this, a preliminary examination of the 
kinetics of an acute and chronic dose of the drug was 
performed in order to correlate the plasma 
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Fig. 3.1.6. Copper levels in (a) serum and (b) urine 
from control rats and rats treated daily 
from day 0 with D-penicillamine 
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Fig. 3.1.7. Changes in body weight of control (•— • ) 
rats and rats treated daily with 
200 mg/kg D-penicillamine p.o. (ft —  ■ )
(n = 4 + S.E.M.)
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3.1.3 Kinetics of an Acute and Chronic Oral Dose of 
200 mg/kg D-Penicillamine.
Initially, female, Sprague-Dawley rats weighing between 
120-160g were given a single oral dose of 
D-penicillamine (200 mg/kg). Individual rats were bled, 
then sacrificed, at various time-points over the 
subsequent 7 2 hours (3 rats at each time-point). Serum 
was assayed for total D-penicillamine (ie. 
protein-bound, free and disulphides) by the method as 
described in Section 2.7.
Fig. 3.1.8 shows the serum concentration - time curve 
after a single oral dose of D-penicillamine (200 
mg/kg). Peak serum concentrations of 72.9 + 1.5 pg/ml 
(mean + S.E.M.) were observed 45 minutes post-dosing. 
The decline in the serum concentration was biphasic 
with an initial half-life of 27.0 minutes followed by a 
much slower decline with a half-life of 51.02 hours. 
The serum concentrations in this phase at 24 hours were
13.1 + 1.1 pg/ml.
The same procedure as above was repeated for rats that 
had been administered a daily, oral dose of 
D-penicillamine (200 mg/kg) for 15 days. The kinetics 
of the last dose of the treatment course are shown in 
Fig. 3.1.9 . Again, peak serum concentrations occurred
82
jjg/ m  1 
80-]
?0- i .
6 0 -  \
S0-I \
4-0-1 i
3 0  S
2 8 -
10-
—T tY  1---- 7T--------- 1-------- 77-------------1---------
£ 4- 4-8 38 }u'72
Fig. 3.1.8. Total D-Penicillamine in rat serum after a 
single, oral dose of D-penicillamine 
(200 mg/kg), (n = 3, mean +S.E.M.)
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Fig. 3.1.9. Total D-penicillamine in rat serum after 
the last dose of D-penicillamine in a 15 
day course of daily oral treatment with 
200 mg/kg D-penicillamine.
(n = 3, mean + S.E.M.)
at 45 minutes post-dosing, but the mean peak 
concentration was 130.6 + 7.2 pg/ml. The initial and 
final phase half-lives were 51.5 minutes and 61.4 hours 
respectively.The serum concentrations in the second 
phase at 24 hours were 18.4 + 1.5 pg/ml.
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3.2 METABOLISM OF 14C-D-PENICILLAMINE.
14The availabilty of C-D-penicillamine (kindly supplied
by Lilly Research Centre) has allowed a more in-depth
study into the plasma protein binding and metabolism of
the drug. Except for a radiolabel study performed by
Planas-Bohne (1981) using the racemic mixture 
14C-DL-penicillamine there are few other reports on the 
metabolism and disposition of the labelled drug. In 
addition, the identity of the major plasma 
metabolite(s) in rats remains speculative due to the 
lack of a selective, sensitive assay system. This 
section represents the results obtained from 
anesthetized animal studies and the findings in respect 
to metabolism in the rat.
143.2.1 Plasma Decay of C-D-Penicillamine
Control and adjuvant arthritic rats (4 in each group) 
were intravenously dosed with ^4C-D-penicillamine (10 
jaCi; 2 00mg/kg) . For methodology see Section 2.4.4. 
Radioactivity was measured in plasma and protein free 
ultrafiltrate over the subsequent 60 mins. Individual 
metabolites were identified by the radio-TLC system as 
described in Section 2.6.
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14Fig. 3.2.1 shows the decay of C-D-penicillamme in 
plasma against time in control and adjuvant arthritic 
rats. Radioactive counts were significantly lower in 
the AA rats (p<0.05) during, but not after, the 4-5 
minute equilibration period. The plasma radioactive 
decay was bi-exponential in both cases. The short rapid 
half-life was longer in the AA rats (4.52 min.) than in 
the controls (3.14 min.). The second phase half-lives, 
however, showed no significant difference between 
controls and AA rats (2.13 hours and 2.33 hours 
respectively - see table 6). In order to obtain truly 
accurate figures for the final half-lives, plasma decay 
should be measured over a time period twice the 
half-lfe value. However, this was not practically 
possible.
3.2.2 Bound and Free D-Penicillamine.
By measuring the counts in plasma and protein-free 
ultrafiltrate within 60 mins. post-dosing, the 
percentage of the drug bound to plasma proteins can be 
calculated. The initial plasma protein binding of 
D-penicillamine in the AA rat was 43.3 + 1.9%,
significantly lower (p<0.05) than in the controls where 
plasma protein was found to be 62.5 + 5.8%. However, 
both groups rapidly reached an equilibrium of around 
55% protein binding at 1 hour post-dosing. (Fig. 















Fig. 3.2.1. Plasma radioactive decay after
14an intravenous dose of C-D-penicillamine 
(200 mg/kg:10 pCi) in normal and adjuvant 
arthritic rats (n=4, mean + SEM).
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Fig. 3.2.2. Binding of ^C-D-penicil lamine to plasma 
proteins in normal and adjuvant arthritic 





tl/2 (initial) 3.14 min 4.52 min
tl/2 (final) 2.13 hours 2.33 hours
14C protein binding 
(60 sec)
62.5+5.8% 43.4+1.9%
14 . . .C protein binding
(30 min)
56.9+3.7% 54.5+3.1%
14Table 6 Disposition of C D-Penicillamine in
Control and Adjuvant Arthritic Rats (n=4) 
(n=4, mean + S.E.M.)
90
D-penicillamine in these samples (sample volume = 0.3 
ml whole blood), it can be reasonably assumed that the 
concentration will be similar to that observed after an 
acute intravenous dose of "cold" D-penicillamine 
(Section 3.3, Fig. 3.3.1). Thus a percentage binding of 
55% relates to a bound plasma concentration of between 
40-50 pg/ml at 1 hour.
In addition to the radiolabel binding study, free 
penicillamine was measured by HPLC in the serum of 
normal rats intravenously dosed with 2 00 mg/kg 
D-penicillamine. Table 7 shows that the free thiol 
gradually disappears from the blood until at 3 hours 
post dosing it is undetectable due to the limit of 
sensitivity of the HPLC system which was 0.1 pg/ml.
3.2.3. Metabolite Identification.
The results in Fig. 3.2.3 show that in both the AA and 
controls the major plasma metabolite was penicillamine 
disulphide with a small proportion of free 
penicillamine present initially. However,
penicillamine-cysteine disulphide was undetectable in 
the plasma of either group. It should be remembered 
that although the method of identification may be 
qualitative, it is certainly not accurate or sensitive 
enough to be quantitative. Hence penicillamine cysteine 




Cone, free PSH 
(pg/ml)
Cone, total PSH 
(pg/ml)
%f ree
0.25 11.26+0.1 272.0+1.5 4.1
0.5 5.87+0.1 127.4+11.6 4.6
1.0 2.84+0.05 80.7+13.2 3.5
2.0 0.8 + 0.05 26.4+4.4 3.0
3.0 not detected ---
Table 7. Percentage of free D-penicillamine after 
a 200 mg/kg intravenous dose 
(n=3, mean + S.E.M.)
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Fig. 3.2.3. Radio-TLC of ultrafiltrate obtained from
plasma from normal and adjuvant arthritic
rats at (i) 20 sec. and (ii) 60 mins after
14an intravenous dose of C-D-penicillamine
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quantities for detection. However, if the presence of 
penicillamine cysteine is considered to be just 
indistinguishable from backgound counts, an estimate of 
the minimum PSSP:PSSC ratio can be obtained from DPM at 
the PSSP spot divided by 2 (to account for twice the 
penicillamine content) related to the background DPM. 
This gives a minimum estimated PSSP:PSSC ratio of 14:1 
in the rat.
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3.3 THE PHARMACOKINETICS OF D-PENICILLAMINE AND 
ITS DISULPHIDES•
3.3.1 Total Seram D-Penicillamine Levels
The study of the pharmacokinetics and metabolism of 
D-penicillamine has in the past been limited by the 
absence of a reliable analytical technique for 
separation and quantification of the metabolites of the 
drug (See section 1.1.5). In order to overcome this 
problem, the metabolism and disposition of 
D-penicillamine, penicillamine disulphide (the major 
metabolite identified in rat serum in Section 3.2) and 
penicillamine cysteine (the principle metabolite in 
humans), was investigated by the measurement of total 
serum D-penicillamine levels after oral and intravenous 
dosing with the individual compounds. For comparitive 
purposes the disulphides were administered at equimolar 
equivalents of 200mg/kg D-penicillamine, ie 202 mg/kg 
penicillamine disulphide, and 362 mg/kg penicillamine 
cysteine.
Female Sprague-Dawley rats weighing between 120-160g 
were given either a single intravenous or oral dose of 
one of the D-penicillamine compounds at the dosage 
levels stated above. Blood was then taken and the rat
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sacrificed at various time points over the subsequent 
72 hours (3 rats per time point). Serum was assayed for 
total D-penicillamine (Section 2.7).
The pharmacokinetic profiles of D-penicillamine after 
oral and intravenous dosing are shown in Fig. 3.3.1. 
Peak serum concentration after oral dosing occurred at 
45 mins post-dosing and was 72.9 + 1.5 pg/ml. The
decline in the serum drug concentration was biphasic 
with an initial rapid half-life of 27.0 mins followed 
by a much slower decline of 51.0 hours. The areas under 
the curve (AUC) value (0-8 hours), as calculated using 
the trapezoidal rule, after oral and intravenous dosing 
were 214 + 17.1 and 331 + 18.3 mg.h/L respectively,
giving an oral biovailabilty of 64.8%.
Fig. 3.3.2 shows the fate of penicillamine disulphide 
(PSSP) after oral and intravenous dosing and the 
kinetic profiles are shown in comparison with 
D-penicillamine in Figs. 3.3.3 and 3.3.4. Penicillamine 
disulphide is poorly absorbed from the gut, peak serum 
concentrations being only 4.67 + 0.7 pg/ml and
occurring 1 hour after administration as compared to 
72.9 + 1.5 pg/ml at 0.75 hours for D-penicillamine
(p<0.001) The oral data shows a monophasic decline in 
serum penicillamine levels, in contrast to the biphasic 
decline exhibited after intravenous dosing. The values 
for initial and terminal phase half-lives calculated
96
P i s -u
Fig. 3.3.1 Lo9^q total D-penicillamine in serum
vs. time after a single oral (•— •) and
i.v. (B— B) dose of 200 mg/kg PSH.
Values are the mean of 3 rats. For 
simplification of the graph, SEM are not 
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Fig. 3.3.2 Lo9^o tota  ^D-penicillamine in serum
vs. time after a single oral (•--•) and
i.v. (■— B) dose of 202 mg/kg PSSP. 
Values are the mean of 3 rats. For 
simplification of the graph, SEM are not 
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Fig. 3.3.3 Lo9^o D“Penicillair>ine i-n serum
vs. time after a single oral dose of
200 mg/kg PSH (*--■ ) and 202 mg/kg
PSSP (•--•). Values are the mean of 
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Fig. 3.3.4 Lo9^0 tota -^ D“Penicillamine in serum
vs. time after a single i.v. dose of 
200 mg/kg PSH (■— ■ ) and 202 mg/kg 
PSSP (•--•). Values are the mean of 
3 rats + SEM.
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from the iv results are 18.1 mins and 62.7 hours 
respectively. The AUC after oral dosing was only 5.2 +
0.8 mg.h/L and 214.9 + 12.3 mg.h/L after i.v., both 
values considerably lower than those obtained after 
D-penicillamine administration (214 +17.1 and 331 +18.3 
respectively).
Figs. 3.3.5, shows the kinetic profiles obtained after 
acute oral and intravenous penicillamine cysteine 
(PSSC) treatment. Figs. 3.3.6 and 3.3.7 show these 
kinetics in comparison to the D-penicillamine data. 
Peak serum D-penicillamine concentrations occur at 1 
hour post oral dosing with PSSC and are significantly 
lower at 5 5.7 + 5.7 ug/ml as compared to 72.9 + 1.5 
pg/ml at 0.75 hour for D-penicillamine (p<0.05). This 
reduced absorption of the drug is again highlighted by 
the AUC for penicillamine cysteine being only 184.9 +
13.3 mg.h/L after oral administration as compared to 
214 + 17.1 for D-penicilamine. However, the AUC^v of 
385 + 25.2 mg.h/L, is not significantly different from 
the AUC of 331 + 18.3 obtained after iv treatment with 
D-penicillamine. The biphasic decline in total serum 
D-penicillamine is apparent, with an initial half-life 
of 24.9 mins and a terminal phase half-life of 35.8 
hours.
Free D-penicillamine was detectable only in samples 
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Fig. 3.3.5 Log^^ total D-penicillamine in serum
vs. time after a single oral (•--•) and
i.v. (■— -*) dose of 362 mg/kg PSSC. 
Values are the mean of 3 rats. For 
simplification of the graph, SEM are not 
shown, but are indicated in Appendix 3
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Fig. 3.3.6 Log^ total D-penicillamine in serum 
vs. time after a single oral dose of
200 mg/kg PSH (■--■ ) and 362 mg/kg
PSSC (•--•). Values are the mean of 
3 rats. For simplification of the graph, 
SEM are not shown but are indicated in 
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Fig. 3.3.7 Log^Q total D-penicillamine in serum 
vs. time after a single i.v. dose of 
200 mg/kg PSH (■— ■) and 362 mg/kg 
PSSC (•— •). Values are the mean of 
3 rats. For simplification of the graph, 
SEM are not shown but are indicated in 
Appendix 1 and 3
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rate of disappearance of the free drug is shown in 
Table 7, Section 3.2.
A summary of the pharmacokinetic parameters obtained 
after a single oral and iv dose of D-penicillamine and 
its disulphides is shown in Table 8.
3.3.2. Urinary Excretion of D-Penicillamine.
Female Sprague-Dawley rats weighing between 120-160g 
were intravenously dosed with either D-penicillamine 
(200 mg/kg), penicillamine disulphide (202 mg/kg) or 
penicillamine cysteine (362 mg/kg). Four rats per 
dosage group were used. Urine was collected over the 
subsequent 24 hours and assayed for D-penicillamine 
after reduction to the free thiol as described in 
Section 2.7.
The excretion of D-penicillamine in the urine after 
intravenous administration of penicillamine disulphide 
and penicillamine cysteine, as compared with 
D-penicillamine are shown in Figs. 3.3.8 and 3.3.9 
respectively. With all three compounds, the majority of 
the excretable D-penicillamine was recovered in the 
urine 0-4 hours post-dosing. The urinary excretion 
profile after penicillamine cysteine treatment is not 
significantly different from that after D-penicillamine 

























Table 8. Pharmacokinetic Parameters following a Single
Oral and Intravenous Dose of D-Penicillamine 
(PSH), Penicillamine Disulphide (PSSP) and 
Penicillamine Cysteine ®(PSSC). All doses 






Fig. 3.3.8 Urinary excretion of total D-penicillamine 
in the 4 8 hour period after an intravenous 
dose of 200 mg/kg PSH and 202 mg/kg PSSP. 





Fig. 3.3.9 Urinary excretion of total D-penicillamine 
in the 48 hour period after an intravenous 
dose of 200 mg/kg PSH and 362 mg/kg PSSC. 
(n=4, mean + SEM)
108
and 47.7 + 4.9% respectively. However, total urinary 
output after penicillamine disulphide was significantly 
higher than after D-penicillamine in the 0-4 hour 
period post-dosing (p<0.02). Total excretion over the 
48 hour time-course was 69.1 + 5.0% of the dose given 
(Table 8).
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3.4. THE EFFECTS OF D-PENICILLAMINE AND PENICILLAMINE 
CYSTEINE ON ADJUVANT ARTHRITIS.
As reviewed in Section 1.3, there are very few animal 
models of arthritis in which D-penicillamine exhibits 
disease modifying activity. This may be, in part, due 
to differences in metabolite formation in humans and 
the rat. Section 3.2 has shown that the major 
metabolite in the blood of the rat is penicillamine 
disulphide with small amounts of free parent drug. No 
penicillamine cysteine was detectable, the 
predominantly occurring metabolite occurring in humans. 
It has been suggested (Nakaike et al, 1983), that 
penicillamine-cysteine may have an immunomodulatory 
effect and therefore may be the active species in RA 
therapy with D-penicillamine. Hence it was of interest 
to assess the effects of this compound on the 
development of adjuvant arthritis, the most popular 
model for assessing potential anti-rheumatic agents and 
one in which D-penicillamine itsef appears to have 
little disease modifying activity.
3.4.1 Effects on Arthritic Parameters
Arthritis was induced in female Sprague-Dawley rats by 
an injection of 0.05 ml Complete Freund's Adjuvant 
containing heat killed M. tuberculosis (2.5 mg/ml) into 
the right hind paw. The development of the disease was
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monitored by increase in foot volume, changes in body 
weight and arthritic score over an 18 day period. The 
effects of daily, oral treatment of D-penicillamine 
(200 mg/kg) and penicillamine cysteine (362 mg/kg) 
commencing 1 day prior to AA induction, on each of 
these parameters was obseved. Control AA rats were 
dosed with vehicle only (n = 6 in each treatment
group).
An intense but transient inflammatory response occurred 
immediately after injection of the adjuvant. This 
initial phase of acute inflammatory response was local 
and produced no other obvious reactions in the animals 
other than a marked increase in foot volume (Fig. 
3.4.1). Over the subsequent 7 days after innoculation, 
the injection site gradually necrosed but the animals 
retained a generally healthy appearance, with no 
further increase in foot volume. However, 9 days into 
the course, a marked change began to occur. The 
injected hind paw began to swell and extensive 
arthritic inflammation appeared in areas remote from 
the injection site. The distal small joints of both 
hind paws were affected with varying degrees of 
severity and mobility. At this time, swelling of the 
left hind paw also became apparent. The forepaws and 
tails of the rats were commonly distended and in the 
most drammatically responding animals, the eyes, nose 
and ears became deformed. In all animals that developed
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the disease, a retardation in weight gain was recorded 
(Fig. 3.4.3) and, on occassions, actual weight loss.
As illustrated in Figs. 3.4.1 and 3.4.2 treatment with 
either D-penicillamine or penicillamine cysteine failed 
to significantly modify the swelling in right or left 
hind paw. Also, there was no effect of either compound 
on the retardation of weight gain, AA animals 
increasing in body weight by only 44g as compared to 
77g in normal rats (Figs. 3.4.3a and b) . Arthritic 
scores in both AA controls and the two drug treated 
groups are shown in Fig. 3.4.4. AA control rats reached 
a maximum score of 9.1 + 0.4 on day 18. Daily oral
treatment with either D-penicillamine or penicillamine 
cysteine did not significantly alter the score, being
8.3 + 0.4 and 8.1 + 0.6 respectively (p>0.05) at the 
end of the course.
3.4.2 Total Serum SH Levels During the Development of 
Adjuvant Arthritis
Induction of arthritis and daily oral treatment with 
D-penicillamine (200 mg/kg) and penicillamine cysteine 
(362 mg/kg) was as described above. Rats were bled and 
sacrificed on days 1, 3, 5, 7, 9, 15, 17 after
induction of arthritis (4 rats per treatment group per 
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Fig. 3.4.1 The effect of D-penicillamine
(200 mg/kg/day, p.o.) on the hind paw 
volume during the development of AA. 
(n=6, mean + SEM).
B— ■ AA right hind paw 
□— -Q A A/PSH r ight hind paw 
e— • AA left hind paw 










B— B AA r ight hind paw 
o— □ AA/PSSCright hindpaw 
•— • AA left hind paw 
o— o A A/PSSC left hind paw
Fig. 3.4.2 The effect of penicillamine cysteine 
(362 mg/kg/day, p.o.) on the hind paw 
volume during the development of AA. 
(n=6, mean + SEM).
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s— ■ Normal 
o— o A A - P S H
DAYS.
Fig- 3.4.3(a) The effect of D-penicillamine
(200 mg/kg/day, p.o.) on the change 
in body weight during the development 
of AA. (n=6, mean + SEM).
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Fig. 3.4.3(b) The effect of penicillamine cysteine
(362 mg/kg/day, p.o.) on the change 
in body weight during the development 
of AA. (n=6, mean + SEM).
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B b  A A Control
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1  3  5 7  3  1 1  14r 1 6  1 S DAYS
Fig. 3.4.4 The effect of D-penicillamine
(200 mg/kg/day, p.o.) and penicillamine 
cysteine (362 mg/kg/day p.o) on the 
arthritic score during the development 
of AA. (n=6, mean + SEM).
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content as described in Section 2.5.
The serial changes in total serum sulphydryl levels in 
AA control rats and drug treated rats are shown in Fig. 
3.4.5. In control AA rats, a rapid fall in serum SH 
levels occurred during the acute inflammatory phase ie 
from 53.9 + 1.5 ug/ml on day 0 to 41.5 + 0.6 ug/ml on 
day 3. Levels continued to fall to a minimum of 24.4 + 
0.6 ug/ml on Day 9, around the time of onset of AA. 
Thereafter, serum SH levels began to rise, but at the 
end of the 18 day course were only 33.0 + 2.1 ug/ml, 
significantly lower than 0 time control (p<0.01)
Both D-penicillamine and penicillamine cysteine 
appeared to exacerbate the initial fall in serum 
sulphydryl levels in the acute inflammatory phase. On 
day 3 seum SH levels were significantly lower than the 
AA control rats; 37.5 + 0.9 pg/ml after D-penicillamine 
treatment (p<0.05) and 29.9 + 2.6 ug/ml (p<0.02) after 
treatment with penicillamine cysteine. At around the 
time of onset of AA (Day 9), serum SH levels after drug 
treatment were not significantly different from AA 
controls, but both PSH and PSSC treatment increased the 
the serum SH levels in AA rats towards normality, 
reaching values of 47.8 + 1.9 ug/ml (p>0.05 as compared 
to normals) and 43.4 + 2.1 ug/ml (p<0.05 as compared to 
normals) respectively on day 18.
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Fig. 3.4.5 The effect of D-penicillamine
(200 mg/kg/day, p.o.) and penicillamine 
cysteine (362 mg/kg/day p.o) on total serum 
sulphydryl levels during the development 
of AA (n=4, mean + SEM)
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3.4.3 Serum and Urinary Copper Levels During the 
Development of AA
Induction of arthritis and daily oral treatment with 
D-penicillamine (200 mg/kg) and penicillamine cysteine 
(362 mg/kg) was as described above. Rats were placed in 
metabowls on days 1, 3, 5, 7, 9, 15 and 17 and urine 
collected over the subsequent 24 hours. (4 rats per 
treatment group per day). Animals were then bled and 
sacrificed at the end of the 24 hour period. Urine and 
serum were assayed for total copper content as 
described in Section 2.5.
The changes in serum copper levels during the 
development of AA are shown in Fig 3.4.6. An extremely 
rapid, drammatic rise in serum copper occurred between 
Days 0-1 increasing from a normal value of 1.1 + 0.05 
pg/ml to 2.4 + 0.06ug/ml (p<0.001). Thereafter levels
declined until on Day 7 they were 1.7 + 0.2 ug/ml, just 
significantly different from normal (p<0.05). A second 
rapid increase in serum copper levels was apparent 
increasing to 2.6 + 0.8 pg/ml on day 9 and these levels 
were maintained until the end of the course when serum 
copper was 2.76 + 0.0 9 ug/ml on day 17 (p<0.0 01 AA vs 
normals). Both D-penicillamine and penicillamine 
cysteine returned the serum copper levels to normality 
in the acute inflammation phase (p>0.05 at day 7 for AA
120
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Fig. 3.4.6 The effect of D-penicillamine
(200 mg/kg/day, p.o.) and penicillamine 
cysteine (362 mg/kg/day p.o) on serum 
copper levels during the development 
of AA (n=4, mean + SEM)
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Fig. 3.4.7 The effect of D-penicillamine
(200 mg/kg/day, p.o.) and penicillamine 
cysteine (362 mg/kg/day p.o) on urinary 
copper excretion during the development 
of AA (n=4, mean + SEM)
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rats treated with either compound vs normals). However, 
in the active phase of the disease D-penicillamine and 
penicillamine cysteine were unable to completely 
normalise serum copper levels values being 1.86 + 0.06 
pg/ml and 2.05 + 0.01 yig/ml respectively (p<0.01 either 
compound vs normals) on day 17.
Fig 3.4.7 shows the urinary copper excretion profile 
throughout the adjuvant course. In the AA control rats, 
urinary copper excretion was not significantly
different from values of 4.9 + 0.9 pg/24 hr in normal
rats (p> 0.05). D-penicillamine and penicillamine
cysteine caused a massive increase in urinary copper 
excretion rising to 22.9 + 1.1 pg/24 hr and 18.2 + 2.5 
ug/24 hr respectively on day 1, as compared to 4.7 + 
0.98 pg/24 hr in AA control rats (p<0.001). These
levels were maintained throughout the rest of the 
course.
3.4.4 Total Serum D-penicillamine Levels After Chronic 
Treatment of AA rats with PSH and PSSC.
Female Sprague-Dawley rats were orally dosed with
D-penicillamine (200 mg/kg) or penicillamine cysteine 
(362 mg/kg) for 15 days. In AA rats, treatment 
commenced 1 day prior to innoculation. On day 15 of the 
course, rats were bled then sacrificed at various time
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points over the subsequent 72 hours post-dosing (3 rats 
per time point). Serum was then assayed for total 
D-penicillamine as described in Section 2.7.
The kinetic profiles after daily oral dosing of each 
compound throughout the AA course are shown in Fig 
3.4.8. Peak serum D-penicillamine levels were 121.4 +
11.4 *ig/ml at 45 mins after D-penicillamine treatment 
and 100.5 + 6.7 pg/ml at 1 hour after dosing with
penicillamine cysteine. The initial phase half-lives 
were not significantly different after treatment with 
D-penicillamine or penicillamine cysteine, being 51.4 
mins and 58.3 mins respectively. However, the terminal 
phase half-life after penicillamine cysteine was 53.8 
hours, considerably shorter than the half-life of 64.0 
hours observed after D-penicillamine. Neither compound 
exhibited significant differences in pharmacokinetic 
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Fig. 3.4.8 L o g ^ Q  total D-penicillamine in serum 
after the last oral dose in a 15 day 
treatment course of AA rats of 200 mg/kg 
PSH (•--•) or 362 mg/kg PSSC (■— ■). Values 
are the mean of 3 rats. For simplification 
of the graph, SEM are not shown but are 
indicated in Appendix 4 and 5.
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PSH PSSC
Normal AA ■ Normal AA
Peak Serum Cone. 130.6 121.4 98.7 100.5
(pg/ml) +7.2 +11.4 +8.6 + 6.7
' AUC0-8 359.4 340.5 312.6 318.9
(mg.h/L) +42.8 +28.9 +27.7 +25.1
Initial phase 57.5 51.4 63.0 58.3
half-life (mins)
Terminal phase 61.4 64.0 56.8 53.8
half-life (hours)
Table 9. Pharmacokinetic Parameters Following 
Chronic Daily Oral Dosing of Normal 
and Adjuvant Arthritic Rats with 200 mg/kg 







4. A COMPARISON OF THE TOXICITY, PHARMACOKINETICS 
AND PHARMACOLOGY OF D-PENICILLAMINE IN MAN AND RATS.
The previous section has given the pharmacokinetic 
profiles of D-penicillamine, penicillamine disulphide 
and penicillamine cysteine in normal and/or adjuvant 
arthritic rats* Their individual pharmacodynamic 
effects on the development of the disease have also 
been assesesed. This section will compare these results 
with published human data and assess the suitability of 
rat adjuvant arthritis as a model for the screening of 
potential anti-rheumatic agents.
4.1 Toxicity of D-penicillamine in Man and Rats
The preliminary experiments on drug tolerance in rats 
as discussed in Section 3.1 have shown that, from the 
parameters measured, female Spague-Dawley rats aged 
between 6-8 weeks (120-160g) can tolerate a daily oral 
dose of 200 mg/kg for 18 day's without any apparent 
adverse effects. Other animal studies have revealed 
strain variabilities (and hence genetic influence) in 
rats to the toxicity of the drug. Whilst male Lewis and 
Sprague-Dawley rats weighing around 150g have been 
reported to tolerate a daily oral dose of up to 50 mgs 
D-penicillamine for 8 months, male Brown Norway rats 
became severely ill after only 3-8 weeks treatment, 
characterized by weight loss dermatitis and a high
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mortality rate (Donker et al, 1984).
Initial toxicological experiments also revealed that a 
dose of 400 mg/kg D-penicillamine induced immediate 
proteinuria and an increase in urinary creatinine in 
the young rats (Section 3.1). Doses of D-penicillamine 
of 400 mg/kg and above, have previously been shown to 
cause an immediate increase in urine volume and 
proteinuria in young, Sprague-Dawley rats 
(Khalil-Manesh and Price, 1983). This increase in 
urinary protein was predominantly due to albuminuria 
and excretion of other low molecular weight proteins. 
Chronic studies by the same group indicated that 
D-penicillamine directly affects the glomerular 
basement membrane of young rats, possibly by 
interfering with cross-link formation.
Adverse reactions to D-penicilamine therapy in man have 
been well documented since the drug came into clinical 
use in 1956. The first double-blind study to show that 
D-penicillamine was effective as compared to placebo 
(Andrews et al, 1973) used doses of 1500-1800 mg daily 
for 12 months. However, as well as disease improvement 
being evident, the trial also highlighted the 
relatively high incidence of complications due to 
D-penicillamine therapy. Since then, there have been 
important changes to the treatment regimen of the drug 
in order to improve tolerance by the patients while
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reducing the side effects. The drug is now generally 
introduced slowly to the patient at 250 mg per day or 
less. This dosage can be maintained for several weeks 
until the natural history of the disease in the patient 
is discerned. The dosage may then be increased to 500 
mg or up to 7 50 mg. A period of at least 7 days should 
elapse before the dose is increased as work performed 
recently in this department has shown that patients 
whose dose was increased within 7 days did not achieve 
steady state conditions on a particular dose 
(Notarianni, personal communication). Marked
interindividual variability in pharmacokinetic 
parameters are well documented features of 
D-penicillamine therapy (Wiesner et al, 1981; Kukovetz, 
et al 1983; Bergstrom et al, 1981a; Brooks et al, 
1984). However, in two studies, one measuring free drug 
(Brooks et al, 1984) and one measuring total drug 
(Muijsers et al, 1984) failed to find any correlation
between D-penicillamine levels and efficacy/toxicity in 
patients taking 250, 500 or 750 mg of the drug. Both
studies emphasised that some of the most common side 
effects observed with D-penicillamine therapy, 
proteinuria and thrombocytopenia, were not connected 
with high drug levels. However, it is probable that the 
vastly supratherapeutic doses used in the earlier 
trials (Andrews et al, 1973) did not lead to any
further clinical improvement, but rather increased the 
risk of complications.
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In addition to the link between dose and side effects 
there have a number of recent reports indicating a 
genetic involvement for the manifestatation of adverse 
reactions induced by the drug. Stastny (1978) 
established an association between rheumatoid arthritis 
and the HLA-DR4 antigen. In the same year, Panayi and 
coworkers (19 78), suggested a genetic predisposition to 
toxic reactions to sodium aurothiomalate and 
D-penicillamine therapy. In 1980 Wooley et al, showed 
that the development of proteinuria in patients treated 
with sodium aurothiomalate or D-penicillamine is 
associated with the presence of HLA-B8 and DR3 antigens 
but found no significant association between these HLA 
antigens and haematological complications of treatment 
with either drug or both drugs. A more recent report 
(Perrier et al, 1985) showed that patients possessing 
HLA-DR3 were at a 10 times greater risk of developing 
skin eruptions or proteinuria after D-penicillamine 
therapy than DR3 negative patients. Also, studies on 
the genetic aspects of the polymodally distributed 
sulphoxidation of the mucolytic agent,
S-carboxymethyl-L-cysteine (carbocysteine), in man 
showed that patients who were found to be deficient 
sulphoxidisers of the drug showed a significant 
increase in the manifestations of toxic reactions to 
D-penicillamine (Emery et al, 1984). The only enzymatic 
metbolism product of D-penicillamine, S-methyl 
penicillamine, is structurally similar to
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carbocysteine. If this metabolite is responsible for 
toxicity it may be that patients who are poor 
sulphoxidisers, and hence less able to remove the drug, 
are more at risk from adverse reactions.
Hence it would seem that in both man and rats 
D-penicillamine has a great propensity to induce toxic 
side-effects, and the degree to which each species is 
at risk is related, in part, to dose and genetic 
background. However, whilst it seems that, in general, 
man only tolerates doses of D-penicillamine of less 
than 1000 mg (approximately 10-15 mg/kg) daily, female 
Sprague-Dawley rats appear to be reaction-free at daily 
doses of 200mg/kg.
4.2 Pharmacokinetics and Metabolism of D-Penicillamine 
and its Disulphides
In. addition to toxicity studies, the pharmacokinetics 
after single and chronic oral dosing of the rats with 
200 mg/kg D-penicillamine have also highlighted several 
species differences when compared to pharmacokinetic 
studies in man. In the rat, maximal drug absorption 
occurred at 45 minutes post-dosing. This was followed 
by a bi-phasic decline in serum drug concentration with 
an initial half-life of 27.0 mins followed by a slower 
decline with a half-life of 51.02 hours (single dose). 
After 15 days chronic oral dosing with 200 mg/kg
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D-penicillamine, peak serum concentrations again 
occurred at 45 mins after the dose was given. However, 
the initial and terminal phase half-lives had increased 
to 51.5 minutes and 61.4 hours respectively. These 
values are greatly different from the pharmacokinetic 
parameters obtained from studies in man. Most groups 
report that peak serum concentrations occur at around 
1-3 hours after oral dosing in man (Wiesner et al, 
1981; Bergstom et al, 1981; Butler et al, 1982; Russell 
et al, 1979 and Kukovetz et al, 1983). A bi-phasic 
decay in the serum is also reported but with values of 
1.5-3 hours for the rapid elimination phase and a 
terminal phase of between 4-6 days (Muijsers et al, 
1979; van der Korst et al, 1981, Muijsers et al, 1984). 
Despite these differences, however, the serum levels 
obtained 24 hours post-dosing in the chronically 
treated rats are not dissimilar to those reached by 
patients taking 500 mg/day at steady state (Table 10, 
courtesy of Dr. L.J. Notarianni). It is not 
unreasonable to assume that patients taking 750 mg/day 
may easily reach levels of 19 pg/ml, as seen in the rat 
after 15 days chronic oral dosing with 200 mg/kg.
Due to the absence of a specific assay for the 
identification and quantification of the metabolites of 
D-penicillamine, few reports on this area of metabolism 
are available. From the limited studies performed to 








125 mg 5.12 + 0.24 (1.72-8.44) n=53
250 mg 8.55 + 0.59 (5.41-14.1) n=24
375 mg 9.89 + 0.10 (5.28-16.4) n=10
500 mg 12.94 + 1.18 (8.60-17.2) n=7
Table 10 Total D-penicillamine Plasma Concentrations 




metabolite is penicillamine-cysteine with small amounts
of penicillamine disulphide and S-methyl penicillamine
(Jellum and Skrede, 1976; Perrett, 1981). However, from
14the work performed with C-D-penicillamine in rats, as 
described in Section 3.2, it would appear that in the 
rat, penicillamine disulphide is the predominant 
metabolite. Free D-penicillamine in rat serum initially 
accounted for 4% of the total (i.e. 11.3 pg/ml) but was 
undetectable 3 hours after dosing. Protein bound 
D-penicillamine was found to equilibrate to 55% at 1 
hour after dosing, representing around 45 pg/ml 
D-penicillamine bound to proteins. This would suggest 
that the remaining 40% of the drug was present as 
disulphide(s). Penicillamine cysteine could not be 
detected, but as mentioned earlier this may be due to 
the lack of sensitivity of the detection system but a 
minimum PSSP:PSSC ratio was speculated to be greater 
than 14:1 (see Section 3.2). The most comprehensive 
study to date on the pharmamacokinetics and metabolism 
of D-penicillamine is by Kyogoku et al (1982) in which 
they measured blood and urine levels of free 
D-penicillamine, penicillamine cysteine and
penicillamine disulphide in man, dogs and rats using a 
combination of HPLC and amino acid analysis. They found 
that in human blood the ratio of free PSH:PSSC was 1:3, 
and that PSSP was undetectable. However, in the rat, 
free PSH was predominant, with ratios of PSH:PSSC being 
8:1 and PSH:PSSP being 15:1; PSSC:PSSP was around 2:1.
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However, this study may be criticized in that only free 
D-penicillamine was measured and, as discussed 
previously, the method of protein precipitation with 
acid may release bound penicillamine which would be 
maintained as free thiol at the low pH. Although these 
results differ from the findings in this thesis, both 
indicate basic differences in metabolism of 
D-penicillamine in man and rats.
From this apparent discrepancy in metabolite formation 
in man and rat an investigation into how the rat 
handles each of the metabolites was performed. Although 
the experiments were limited to the measurement of 
total D-penicillamine in the serum and urine, it was 
still possible to examine the disposition of each 
metabolite after oral and intravenous doses. For 
comparitive purposes, doses of each compound were 
equivalent to 200 mg/kg of D-penicillamine. Although 
penicillamine cysteine showed considerable absorption 
from the gut, less than 3 % of the administered dose of 
penicillamine disulphide appeared in the serum. In both 
cases the peak serum concentrations occurred at 1 hour 
post-dosing, 15 minutes later than the peak observed 
after D-penicillamine treatment. Calculating the oral 
bioavailability from the AUC values after oral and 
intravenous administration, the bioavailabilities of 
D-penicillamine and penicillamine cysteine are 64.8 + 
1.6% and 48.1 + 2.8% respectively. The value for
D-penicillamine is in accordance with other studies in 
rats which report figures of between 55-65% 
(Planas-Bohne, 1972; Ruiz-Torres and Kurten, 1974; 
Patzchke and Wegner, 1977). Absorption rates of 
D-penicillamine in man have been reported to be between 
50 - 62% in the fasting situation, depending on the
drug formulation (Kukovetz et al, 1983). A study by 
Miners (1984) on the reversible metabolism of 
D-penicillamine in the rat in which the presence of 
reduced penicillamine in the plasma after oral and iv 
dosing of D-penicillamine and its disulphides was 
measured implies almost complete absorption of 
penicillamine cysteine, but insignificant absorption of 
penicillamine disulphide. As with the Kyogoku study,
(1982) free penicillamine was measured after the plasma 
had been acidified, which may release variable amounts 
of protein-bound drug leading to false reduced plasma 
penicillamine levels. The study also showed that 
D-penicillamine and its disulphides are
interconvertible in the rat.This effect has also been 
demonstrated with captopril, which like
D-penicillamine, contains a reduced thiol group and is 
known to form disulphide metabolites (Lan et al, 1982; 
Drummer and Jarrott, 1983).The enzymes involved in the 
reduction process are as yet unknown, but it has been 
suggested by Lan et al (1982) that glutathione 
reductase, thiol-disulphide transhydrogenases and 
non-specific disulphide reductases may all have a role
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to play.
The pharmacokinetic data produced after oral and iv 
administration of D-penicillalmine and its disulphides 
show a bi-pasic decline in total serum D-penicillamine 
levels in all cases except after oral dosing with 
penicillamine disulphide (Section 3.3). However, the 
radiolabelled data reveals the existence of a third 
phase after intravenous D-penicillamine treatment. The 
half-life of this phase is extremely short, 
approximately 3 mins in normal rats (Section 3.2). It 
may be that this very rapid initial phase is the 
formation of disulphides, followed by an elimination 
phase in which free base and disulphides are excreted. 
The terminal, slow phase presumably represents the 
"deep" pool, the nature of which is as yet unknown, but 
may be collagen and elastin rich tissues, such as skin 
and bone (Patzchke and Wegner, 1977). The chronic 
administration data (Section 3.4) show that the 
terminal phase half-life of D-penicillamine in serum 
increases from 51.02 hours to 61.4 hours after daily 
oral D-penicillamine treatment and from 35.8 hours to 
56.8 hours after oral dosing with penicillamine 
cysteine during treatment. Studies by van der Korst et 
al (1981) showed only slowly reversible binding of 
D-penicillamine to tissue compartments. It is likely, 
therefore, that the increase in terminal phase 
half-life on repeated dosing is due to the filling of
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this "deep" pool from which the drug is only slowly 
released.
Penicillamine disulphide administered intravenously to 
the rat was rapidly removed from the serum and excreted 
in the urine, (section 3.3) approximately 70% of the 
given dose appearing in the urine within 48 hours of 
administration, almost all of this in the 0-4 hour 
period. In comparison, approximately 45% of the given 
dose of D-penicillamine or penicillamine cysteine was 
recovered in the 48 hours post-dosing, again the 
majority of which is excreted in the first 4 hours. 
This is consistent with the radiolabelled studies of 
Patzchke and Wegner (1977), who report urinary 
excretion rates of D-penicillamine in rats of 52% in 8 
hours. It is not possible to correlate these values to 
urinary excretion rates in man due to the difference in 
route of administration of D-penicillamine. However, 
all studies report that an oral dose of the drug to 
humans results in a maximal excretion rate within 4 
hours after the dose was received. Values of between 
30-40% of the oral dose are reported to be recovered in 
the urine, incomplete absorption of the drug probably 
accounting for the low value (van de Stadt et al, 1979; 
Patzschke and Wegner, 1977).
It would appear, therefore, that penicillamine 
disulphide is less able to remain in the body than
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D-penicillamine or penicillamine-cysteine. It is 
probable that in order for D-penicillamine levels to be 
maintained, binding to serum proteins is important, 
although this binding is readily reversible (van de 
Stadt et al, 1979). The capacity for the disulphides to 
undergo reduction to the free parent drug, is therefore 
important. Work by Theriault and Rabenstein (1985) has 
shown that formation of penicillamine disulphide is via 
a two step process:
•<1
PSH + CSSC ^  PSSC + CSH
k2
3^
PSH + PSSC^=± PSSP + CSH 
They calculated the rate constants at physiological pH 
to be k^=4.66, k2=0.024,and ^=0.116. It would seem
therefore, that in vitro under physiological conditions 
D-penicillamine will form the symmetrical 
penicillamine disulphide (PSSP) via penicillamine 
cysteine (PSSC) formation. The rate constants would 
indicate that the spontaneous reduction of either 
disulphide back to free thiol is negligible. However, 
the ability of the disulphides to undergo enzymic 
reduction is also of importance. It may be that the 
reduction of penicillamine disulphide is subject to 
steric hinderance (due to the extra methyl groups on 
the (3 carbon), moreso than reduction of penicillamine 
cysteine. However, some interconversion between 
penicillamine disulphide and free base seems to occur,
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accounting for the terminal phase seen after 
intravenous administration. A monophasic decline in 
serum concentrations is seen after oral administration 
of the disulphide presumably because the elimination 
rate is faster than the rate of conversion to free 
D-penicillamine. In comparison, the intravenous dose 
kinetics seen with penicilamine cysteine are very 
similar to those of D-peinicillamine, differing only in 
a much shorter terminal phase half-life. The 
spontaneous formation of penicillamine disulphide in 
rat serum, and the relative unavailability of this 
compound for enzymic reduction may explain the much 
shorter half-lives seen in rats than in man.
4.3 The Effects of D-Penicillamine and its Mixed 
Disulphide (PSSC) on Rat Adjuvant Arthritis
In spite of the effectiveness of D-penicillamine in the 
treatment of rheumatoid arthritis, its effect in animal 
models is weak and variable. The failure to detect a 
clear-cut effect of the drug in experimental animals 
may be due to the difference between the major compound 
in the blood of rats and that of humans. It was 
therefore decided to examine the effect of 
penicillamine cysteine, generally considered to be the 
major metabolite in human blood, on one of the animal 
models of arthritis. Out of all the models described 
previously in Section 1.3, rat adjuvant arthritis best
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suited the requirements. It is easily induced and 
monitored, with a high percentage of the innoculated 
animals developing the disease to a uniform degree. The 
disease time course was also reasonably short, avoiding 
the need for prolonged drug therapy. The effects of 
D-penicillamine on the development of the disease were 
also recorded.
Daily, oral D-penicillamine treatment (200mg/kg) from 
day -1 to day 18 had no effect on the various 
parameters used to evaluate disease severity (i.e. hind 
paw volumes, weight change). These observations are in 
accordance with the results of Liyanage and Currey 
(1972) who also found that the same dose of 
D-penicillamine failed to modify AA in rats. Similar 
results were also obtained by Dunn et al (1984) whereby 
oral pretreatment (1-3 months) of AA rats with 
D-penicillamine (100 mg/kg p.o) followed by daily 
treatment after AA induction had no effect on the 
progression of the disease. Indeed, in some studies, 
the drug has been shown to exacerbate the secondary 
lesions of AA (Binderup et al, 1976). Penicillamine 
cysteine treatment on the same schedule also failed to 
show any significant effects, either moderation or 
exacerbation, of the disease process.
Subnormal levels of serum sulphydryl groups have been 
observed in various connective tissue disorders
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including rheumatoid arthritis (Lorber et al, 1971) and 
with high rheumatoid factor titres (Kosaka, 1979). A 
depression in serum SH levels was found in rats that 
developed AA, associated with the persistent chronic 
inflammatory phase of the disease. Maximal depression 
of serum SH occurred at around the time of onset of AA 
(day 9) although a change was noticeable as early as 1 
day after AA induction. These results are consistent 
with the findings of other workers (Butler et al, 1969; 
Lorber et al, 1975). According to Lorber et al (1975) 
the depressed serum SH levels observed in the adjuvant 
rat were not due to the acute inflammatory phase or to 
decreased food consumption or loss of body weight. 
However, this depression may be caused by oxidative 
species, especially H2O2 by activated phagocytes (Hall 
et al, 1984) in the active inflammatory phase when 
gross tissue injury occurs. A similar process has been 
reported in rheumatoid patients (Thomas and Evans, 
1975) where the depression in serum SH levels was 
suggested to be due to oxidation of cysteine 
side-chains within protein structures (predominantly 
albumin) with low molecular thiols such as cysteine and 
glutathione.
Experiments with D-penicillamine showed that although 
chronic treatment with the drug did not alter normal 
serum sulphydryl levels, it increased the serum SH 
levels in AA rats towards normality during the active
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inflamation phase. However, it further reduced SH 
levels in the initial acute inflammation stage (days 
1-3). Penicillamine cysteine showed a similar pattern 
of serial changes, further exacerbating the reduction 
in serum SH levels in the acute inflammatory phase. It 
may be that the supplementation of cysteine levels with 
penicillamine cysteine administration serves to further 
increase the oxidation of serum protein sulphydryl 
groups in this phase. However, in the later persistent 
chronic inflammation phase, it would appear, that both 
compounds are acting as reducing agents, restoring the 
free SH groups that have been blocked by other low 
molecular weight thiols in active AA. D-penicillamine 
has no effect on the mediators of acute inflammation, 
eg prostaglandins accounting for its lack of effect in 
the acute phase of the disease. This reductive ability 
of the compounds may be important in thiol dependent 
reactions of the immune system such as lymphoid cell 
proliferation (Broome and Jeng, 1973) and antibody 
responses (Click et al, 1972).
Both rheumatoid arthritis and adjuvant arthritis are 
characterised by high levels of serum copper (Bajpayee, 
1975; Gralla and Wiseman, 1968). In this study, serum 
copper levels were shown to be elevated as early as day 
1 after induction of AA. These levels began to fall 
gradually until the time of onset of the active 
inflammatory phase, thereafter remaining high. Urinary
144
copper excretion remained at a normal rate throughout 
the course. Although both D-penicillamine and
penicillamine cysteine brought about a reduction of the 
serum copper levels towards normality in the acute 
phase, they could not totally control the increase from 
day 9 onwards. This serum copper reduction was
reflected by the increase in urinary copper output 
throughout the course, a phenomenon also seen in normal 
rats treated with D-penicillamine. One of the 
characteristics of severe inflammation is the presence 
of "acute phase reactants" in the serum. These include 
elevated levels of fibrinogen, several glycoproteins 
and the copper-containing protein caeruloplasmin.
However, there is some dispute as to whether 
caeruloplasmin levels are significantly increased in 
arthritic diseases (Pruzanski et al, 1973). The excess 
copper may therefore be associated with another serum 
component, believed primarily to be albumin, and that 
it is this labile albumin-bound copper that is 
accessible to chelating agents (Whitehouse, 1976). It 
is believed that in rheumatoid arthritis the 
penicillamine-copper chelate exerts a beneficial effect 
by virtue of its superoxide dismutating activity. 
Indeed, Sorenson (1976) has shown that copper complexes 
of many anti-inflammatory drugs including 
D-penicillamine are more active than their parent 
compounds in experimental inflammatory models. However, 
this is not reflected in this study of AA, as no
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improvement of the disease was apparent.
Despite alterations in serum sulphydryl levels and 
protein binding in AA, the pharmacokinetics of 
D-penicillamine or penicillamine cysteine were not 
significantly different in normals than in AA rats. The 
initial decrease in protein binding of D-penicillamine 
in AA rats is probably due to the decrease in the 
number of available serum sulphydryl sites. This is 
only important, however, in the initial period after 
dosing, when there is a considerable amount of free 
D-penicillamine still present in the serum, and 
equilibrium is soon reached between protein bound drug 
and disulphide(s) . Also, the results show that both 
D-penicillamine and penicillamine cysteine restore the 
serum sulphdryl levels towards normality during the AA 
course.
The administration of penicillamine cysteine to 
adjuvant arthritic rats failed to modify the disease 
process at all, and behaved similarly to
D-penicillamine. This is contrary to a report by 
Nakaike et al ( 1983) in which they found 
penicillamine-cysteine to strikingly enhance the
development of AA which they attributed to the
elimination of suppressor cells. However, it would seem 
from the results described earlier, that penicillamine 
cysteine is merely a supply of free penicillamine and 
is inactive per se. In a clinical trial on 
D-penicillamine in 1979, Munthe et al found that the
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addition of cysteine to treatment raised the level of 
erythrocyte glutathione and, in some cases, turned 
non-reponders into responders. There have also been 
tentatative suggestions that serum cysteine depletion 
is related to the incidence of D-penicillamine induced 
side-effects (van der Korst et al, 1981? Muijsers et 
al, 1984). However, this study in the AA rat has failed 
to reveal any beneficial effects of added dietary 
cysteine in the form of penicillamine cysteine.
In conclusion, it would appear that there are major 
differences in the metabolism of D-penicillamine in man 
and the rat. Penicillamiine disulphide is the major 
metabolite in the blood of the rat, which is less 
succeptible to enzymic reduction than penicillamine 
cysteine, the predominant metabolite in humans. The 
existence of the free thiol would appear to be 
neccessary for the maintenance of D-penicillamine in 
the body and the poor in vivo reduction of 
penicillamine disulphide leads to rapid excretion of 
the compound, hence a shorter half-life of 
D-penicillamine in the rat than in humans. The serum 
total penicillamine levels reached after 15 days 
chronic dosing with either D-penicillamine (200mg/kg) 
or penicillamine cysteine (362 mg/kg) were in the same 
order of rheumatoid patients taking 750 mg/kg at steady 
state. Therefore, the lack of response of AA to 
D-penicillamine treatment is not due to insufficient
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serum levels of the drug, or to differences in 
metabolite formation. It is more likely that there are 
major diffences in the aetiology of rheumatoid and 
adjuvant arthritis, which questions the usefulness of 
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Appendix 1. Total serum D-penicillamine concentration





TOTAL [D-PEN] ug/ml 
oral i.v.
0.25 2.5+0.1 231.1+10.9
0.5 3.2+0 . 6 94.2+6.4
0.75 3.9+0 . 9















Appendix 2. Total serum D-penicillamine concentration
after an oral and i.v. dose of 202 mg/kg
penicillamine disulphide (n=3, mean+S.E.M)
JL 74






1.5 36.4+2.7 3 9.6+5.5













Appendix 3- Total serum D-penicillamine concentration
after an oral and i.v. dose of 362 mg/kg
penicillamine cysteine (n=3, mean+S.E.M)
175
T IM E TO TA L [D -P E N ]  u g /m l
h r s . n o r m a l AA
0.25 99.3+4.9 79.5+8.4















Appendix 4. Total serum D-penicillamine concentration 
in normal and AA rats after the last oral 
dose of 200 mg/kg D-penicillamine in a 15 
day oral treatment course. (n=3, mean+S.E.M.)
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T IM E TO TA L [D --P E N ] u g /m l

















Appendix 5. Total serum D-penicillamine concentration 
in normal and AA rats after the last oral 
dose of 362 mg/kg penicillamine cysteine 
in a 15 day oral treatment course.
(n=3, mean+S.E.M.)
